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Highly active antiretroviral therapy (HAART) has enabled people with HIV infection 
(HIV+) to live longer but has also resulted in an increase in aging-related conditions, such as 
frailty.  Chronic inflammation is a hallmark of HAART-treated HIV infection and aging.  
Cytomegalovirus (CMV) infection can cause chronic inflammation and is prevalent in both 
HIV-infected and elderly people.  CMV-specific T cells comprise 10-20% of the T cell pool, 
and in a recent study, T cell responses to CMV correlated with inflammatory markers.  
However, the relationship between CMV levels in peripheral blood mononuclear cells 
(PBMC) and the magnitude of T cell responses to CMV is unknown. 
 
Objectives 
1) To quantify the amount of CMV DNA in PBMC and determine if this amount is related 
to HIV and frailty status; 2) to determine if this amount is related to T cell responses to 
CMV and if this relationship differs by HIV and/or frailty status. 
 
Methods 
Droplet digital polymerase chain reaction (ddPCR) was used to detect rare CMV DNA in 
PBMC from men in the Baltimore-Washington DC site of the Multicenter AIDS Cohort 
(MACS) study with known HIV and frailty status.  Numbers of CMV-responsive T cells 
were compared between donors with and without detectable CMV DNA and among HIV-





CMV DNA was detected in PBMC but levels were unrelated to HIV or frailty status.  
Donors with detectable CMV DNA had higher T cell responses in some cases, and donors 
without detectable CMV DNA had higher responses in other cases, depending on the HIV-
frailty subgroup, the class of T cells (CD4 or CD8), and the specific CMV antigen.  
  
Conclusions 
CMV DNA was quantified in PBMC by ddPCR, and specific CMV DNAs that were or were 
not detected correlated with specific T cell responses to CMV.  These responses may help 
control the amount of CMV DNA, especially responses that were greater when CMV DNA 
was not detected.  Understanding how different CMV strains are related to the T cell 
response to CMV, as well as knowing who will better control CMV infection, may aid in 
vaccine development for CMV and in prevention of inflammation-related conditions. 
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Highly-active antiretroviral therapy (HAART) was introduced in the 1990s to treat people 
infected with human immunodeficiency virus (HIV), and in the almost-three decades since, 
HAART has greatly prolonged the life expectancy of these people (1).  Today, over 45% of 
Americans living with HIV infection are over 50 years old (2).  Despite being on HAART, 
which suppresses the HIV to clinically undetectable levels, people living longer with HIV are 
subjected to age-related chronic conditions known as HIV-associated non-AIDS (HANA) 
conditions.  These HANA conditions include cardiovascular disease and osteoporosis (3), as 
well as frailty, a clinical syndrome that is associated with chronic inflammation (4).  Chronic 
inflammation is a hallmark of HIV infection, even in people receiving HAART, and is 
shown by increased serum concentrations of the pro-inflammatory cytokines interferon-
gamma (IFNγ) and tumor necrosis factor (TNF), among other markers.  The etiology of the 
chronic inflammatory state present in people with treated, virologically-suppressed HIV 
infection is unknown, and many factors may contribute to this, as discussed in section II.B.  
One possible contributing factor is infection with cytomegalovirus (CMV), which causes a 
persistent viral infection.  In support of this possibility, nearly all HIV+ people and elderly 
people are seropositive for CMV.   
 
Chronic inflammation is also a key feature of aging.  Dysregulation of the immune system 
and increased production of inflammatory cytokines such as TNF and interleukin-1 (IL-1), 
contribute to aging-related conditions such as frailty (5).  Frailty is an important clinical 
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condition in aging that results from the failure of many physiological systems (6).  A 
consequence of frailty is an inability to respond effectively to stressors that increase the 
susceptibility to injury and subsequent morbidity and mortality.  Frailty is also associated 
with chronic inflammation, with higher serum concentrations of inflammatory markers in 
frail people (7).  A recent study also linked frailty with CMV infection by identifying 
correlations between the prevalence of CMV-specific T cells and serum levels of 
inflammatory markers such as IFNγ, TNF, and IL-6 (8).  However, no studies have 
addressed the relationship between systemic inflammation and the amount of CMV present 
in the peripheral circulation. 
 
The present study was undertaken to address this gap.  Specifically, this project aimed, first, 
to detect CMV in peripheral blood mononuclear cells (PBMC) from both people with and 
without (HIV−) HIV infection, and second, to determine the extent to which the presence 
of CMV correlates with the magnitude of the T cell response to CMV, as shown by the 
number of T cells producing cytokines in response to stimulation with CMV antigens. 
 
This Introduction provides background on inflammation and its importance in HIV 
infection (see section I.A).  Next, it describes the aging process, focusing on the key role of 
cell damage and senescence (sections I.B.1 and I.B.2), and the significance of chronic 
inflammation in aging (section I.B.3).  Section I.C discusses frailty and its increased 
prevalence in people with HIV and aging, and section I.D discusses characteristics of CMV 
and CMV infection, including its epidemiology (section I.D.1), its structure and genome 
(section I.D.2), its replication cycle (section I.D.3), and the immune responses to the phases 
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of CMV infection (sections I.D.4 and I.D.5).  Section I.D also summarizes the current 
understanding of the latent phase of CMV infection and the connections between CMV 
infection and aging (sections I.D.7 and I.D.8, respectively).  Finally, section I.E discusses 
how the current project built on the previous studies of the role of CMV in the pathogenesis 
of the chronic inflammation seen in both HIV infection and aging.  This Introduction 
concludes with the specific aims and hypotheses of the current project.   
 
 Inflammation and Its Role in HIV Infection A.
1. Inflammation 
Inflammation is defined as a “protective response to stimulation either by pathogens or to 
host cell signals such as cellular damage that results in the clearance of dead or dying cells 
and initiates tissue repair” (5).  It is a significant factor in the pathogenesis of a variety of 
diseases and conditions, such as atherosclerosis, cancer, autoimmunity, chronic infections, 
and aging (4).  As shown in Figure 1.1, inflammation is stimulated by pattern recognition 
receptors (PRRs) expressed on myeloid cells and lymphocytes that sense either highly-
conserved pathogen-associated molecular patterns (PAMPs) or endogenous damage-
associated molecular patterns (DAMPs) (9).  Cellular activation through PAMPs or DAMPs 
results in the production of pro-inflammatory cytokines such as TNF and IL-1β that can 
recruit and activate macrophages locally or exert systemic effects that elicit the production of 
C-reactive protein (CRP) by the liver and activate platelets (5).  The pro-inflammatory 
cytokines activate endothelial cells, which results in increased vascular permeability, allowing 
circulating immune cells to reach the site of infection.  However, it can also cause capillary 
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leakage, vasodilation, and hypotension, which, if not regulated, can be prolonged and can 
become significant problems associated with chronic inflammation.   
Figure 1.1.  Overview of the Inflammatory Response (from (5)).  
This figure shows the various cells that respond to introduction of a foreign substance, 
causing inflammation, and shows the molecules produced by those cells.  Cells such as 
macrophages and T cells produce pro-inflammatory molecules that include cytokines and 
chemokines and have a wide range of effects.  For example, the cytokine IFNγ, which is 
produced by CD4 T cells, activates neutrophils, while IL-22, which is produced by Th17 
cells, stimulates antimicrobial peptides (AMPs) such as defensins (10).  Chemokines, such as 
CCL2, recruit immune cells that are required for phagocytosis and for killing invading 
pathogens.   
 
 
2. Inflammation in HIV Infection 
Chronic inflammation plays an important role in the pathogenesis of HIV infection.  HIV 
infection is associated with an increase in activated T cells (11), inflammatory monocytes, 
and inflammatory cytokines compared to individuals not infected with HIV (12).  Initial HIV 
 5 
infection is associated with rapid release of a large quantity of pro-inflammatory cytokines, 
such as IFNα, IFNγ, TNF, IL-6, IL-10, and IL-15 (13).  The number of activated T cells also 
increases dramatically (14).  Moreover, monocytes play a key role in the inflammation seen in 
HIV infection by producing the pro-inflammatory cytokines IL-6 and TNF (15).  HIV 
infection is also associated with a hypercoagulable state, which in combination with the 
inflammatory environment results in increased morbidity and mortality  (15, 16), and the 
degree of inflammation is prognostic for the progression of HIV infection if it is not treated 
(17).  All of these processes persist through the chronic phases of HIV infection. 
 
Although HAART greatly reduces inflammation, an inflammatory state persists in treated 
HIV+ individuals (18).  People receiving HAART have on average 50% higher serum levels 
of IL-6 than demographically similar people not infected with HIV (15), and IL-6 levels are 
associated with increased risk of mortality and aging-related chronic diseases (16).  Markers 
of monocyte activation such as soluble CD14 (sCD14), derived from circulating monocytes, 
are elevated in HIV-infected people receiving HAART, and are predictive of morbidity (19).  
 
This heightened inflammation and T cell activation could be a result of continuous HIV 
replication (e.g., at very low levels even in virologically-suppressed people receiving 
HAART) (20).  It could also be due to infections with pathogens other than HIV, such as 




Chronic inflammation is also commonly seen in aging (21).  Aging involves the gradual 
accumulation of cellular damage over time.  This accumulation can lead to dysregulation and 
subsequent decline of multiple systems throughout the body, including the immune system.  
The dysregulation of the immune system causes cellular hyperactivity, which in turn can 
cause further inflammation.  
 
1. Cell Damage in Aging 
One of the most common markers of aging is the accumulation of genetic damage (22).  The 
continual threat of DNA damage comes from exogenous factors (e.g., pathogens and 
chemicals) as well as endogenous factors (e.g., errors in DNA replication).  The DNA 
damage that can arise includes point mutations, translocations, chromosomal gains or losses, 
and telomere shortening.  These DNA alterations may modify the expression of genes and 
transcriptional pathways, resulting in cellular dysregulation.  Dysfunctional cells are normally 
removed by apoptosis or senescence, and failure to do so may impact other cells or tissue 
function with numerous significant consequences (e.g., inflammation).   
 
Telomeres, are structures located at the terminal ends of DNA chromosomes which protect 
the chromosomal DNA from the inability of DNA polymerase to effectively replicate the 
DNA at the ends of the chromosome.  The inability of telomeres to fully replicate and their 
gradual shortening over time, makes them particularly susceptible to damage during aging.  
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DNA damage at telomeres induces senescence and/or apoptosis, a function of the normal 
aging process. 
2. Cellular Senescence in Aging 
Along with genetic and cell damage, cellular senescence occurs during the normal aging 
process.  Cellular senescence is the stable arrest of the cell cycle coupled with phenotypic 
changes, such as resistance to apoptosis and various alterations in gene expression (23).  
Senescence can be triggered by telomere shortening (as discussed in section I. B.1), as well as 
by other types of DNA damage, along with de-repression of the INK4/ARF locus and 
dysregulation of other signaling pathways, all of which occur during aging (24).  Senescent 
cells must be removed and replaced by progenitor cells to maintain the cell number and 
prevent system dysfunction.  The increased number of senescent cells in the elderly may 
arise due to an inability to remove these cells, aggravating any damage caused during the 
aging process and contributing to inflammation.   
 
3. The Significance of Inflammation in Aging 
Senescent cells can alter their secretomes to produce large amounts of pro-inflammatory 
cytokines.  The chronic inflammation seen in aging, known as “inflammaging” (25), may 
arise from an accumulation of pro-inflammatory tissue damage.  This is the result of the 
immune system becoming more dysfunctional and less effective at clearing pathogens and an 
increased number of senescent cells that can secrete pro-inflammatory cytokines (21)  
DAMPS, such as extracellular adenosine triphosphate (ATP) and reactive oxygen species 
(ROS), which are elevated during aging (26) and in senescent cells (27), activate the NOD-
like receptor protein 3 (NLRP3) inflammasome.  The NLRP3 triggers the increased 
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production of IL-1β, TNF, and interferons (28).  A result of the increased production of 
pro-inflammatory cytokines is defective inflammatory responses.  Conditions related to aging 
such as obesity, type 2 diabetes (29), and atherosclerosis (30), all exhibit defective 
inflammatory responses that contribute to their pathogenesis.  In addition, inflammation 
inhibits stem cell function, impairing the replacement of dead or damaged cells and 
exacerbating the damage done by the inflammatory environment (31).   
 
“Inflammaging,” together with a decline in the adaptive immune response, prevents the 
immune system from effectively clearing infectious pathogens and infected cells.  Increased 
activation of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) and the 
NF-κB pathway have been identified as key markers of aging (32).  Inflammation (TNF, IL-
1, and IL-6) activates NF-κB in the hypothalamus, which causes a reduction in 
gonadotropin-releasing hormone (GNRH) (33) (Figure 1.1).  Loss of GNRH is associated 
with many aging-related conditions such as bone fragility, muscle weakness, and skin atrophy 
(33).   
 
The most significant changes to the immune system during aging occur in the adaptive 
immune system.  Weakening the immune system leads to an increased susceptibility to 
infections, cancers, autoimmune disease, and chronic inflammatory disease.  Aging is 
associated with an increase in memory cells and a decrease in naïve T cells, especially in CD8 
T cells but also in CD4 T cells (34).  Memory cells protect the host from re-infection with a 
given pathogen, with the survival of memory cells driven by IL-7 or IL-15 (35).  As shown in 
Figure 1.2 (34), in elderly people, repeated exposure to pathogens results in a higher number 
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of differentiated T-effector memory (TEM) cells and a higher number of terminally-
differentiated memory cells re-expressing CD45RA (TEMRA).  The decrease in naïve T cells 
due to thymic involution and exposure to specific antigens, along with the increased number 
of clonally-expanded memory cells, results in an unbalanced naïve/memory cell ratio (36).  
There is a strong correlation between age and the total number of TEMRA CD8+ T cells 
(37).  However, many of these TEMRA are dysfunctional.  The inability of TEMRA to 
produce cytokines in response to stimulation, as well as their inability to proliferate, results in 
memory cells that may be senescent (34).  As discussed in section I.B.2, senescent cells are 
not just dysfunctional but can also trigger inflammatory responses that inflict significant, 
widespread damage. 
Figure 1.2.  Phenotypic Characterization of T Cell Changes in Aging (from (34)).   
During the aging process, there is reduced diversity among the T cell population due to 
thymic involution and clonal expansion.  This figure shows the various markers expressed 
on T cell populations at different stages of differentiation and more highly expressed in 
aging:  Naïve T cells, central memory (CM), effector memory (EM), and terminally 






1. Characteristics of Frailty and the Frailty Phenotype  
Frailty is an important clinical syndrome characterized by a loss of physiological reserves and 
an increased vulnerability to injury, and subsequent morbidity and mortality (38).  In 
addition, frailty results in an inability to respond effectively to daily or acute stressors and 
triggers a downward spiral towards functional decline (38).  Frailty can occur not only with 
aging, but also as a result of a variety of illnesses (e.g., cancer and congestive heart failure) or 
even without any specific disease present.  Frailty has proven difficult to define, but a widely-
used frailty phenotype (FP), known as the Fried FP, is defined as the presence of three or 
more of the following conditions: weakness as measured by grip strength, low physical 
activity, slow motor performance measured by walking speed, exhaustion, and unintentional 
weight loss (39).  Using the Fried FP, the estimated prevalence of frailty in the United States 
is about 10% of men and women age 65 and older (39).  The Fried FP predicts the onset of 
serious conditions such as acute illness, cognitive decline, disability, and mortality (39).  It is 
also an important risk marker for the development of cardiovascular and renal diseases as 
well as some cancers (39).  Moreover, frailty can be a marker for immune decline in the 
elderly and has been used as a marker to identify people who will not respond well to the 




2. The Role of Inflammation in Frailty  
Frailty and chronic inflammation both involve the deterioration and dysregulation of 
multiple physiological systems, and chronic inflammation is one of the possible causes of 
frailty (38).  Frailty is associated with elevated serum concentrations of inflammatory markers 
such as CRP, IL-6, and TNF, which contribute to the pro-inflammatory phenotype and are 
also associated with increased morbidity and mortality (41).  CD8+ CD28- T cells and 
CCR5+ T cells that can produce type-1 pro-inflammatory cytokines are also elevated in 
people with frailty (42).  The potent pro-inflammatory cytokine CXCL-10 is constitutively 
expressed on monocytes and correlated with higher IL-6 levels in frailty (43).  Together, the 
elevated levels of these inflammatory markers suggest that inflammation plays a key role in 
the pathogenesis of frailty.   
 
3. Frailty in People with HIV Infection 
In HIV+ men who have sex with men (MSM), the frailty-related phenotype (FRP) described 
by Desquilbet et al., which uses the same criteria as the Fried FP but without the grip 
strength criterion, serves as a valid measure of frailty in HIV+ men (44).  The FRP was 
shown to have a lower prevalence in people receiving HAART than in those not receiving 
HAART (44).  Additionally, the presence of the FRP when starting HAART was a good 
predictor of overall and AIDS-free survival (44).  In 2007, the MACS began assessing all five 
components of the Fried FP at each study visit.  In one study, the prevalence of the FP was 
12% in HIV+ and 9% in HIV− men, and this prevalence increased with age regardless of 
HIV status but was significantly greater in HIV+ compared with HIV− men aged 50-64 
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(45).  That study went on to show that among FP+ men, 34% HIV+ and 38% HIV− had 
two or more comorbidities (45). 
 
Frailty in virologically suppressed HIV+ people displays inflammation above the levels seen 
in HIV-infected people on HAART.  A study of 24 serologic markers for T cell, B-cell, or 
monocyte activation, was performed on serum stored at each Study to Help the AIDS 
Research Effort (SHARE) study visit (7).  A multiplex assay to detect various serologic 
cytokines (IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p70, GM-CSF, IFN-γ, and TNF) and 
chemokines (CCL2 (MCP-1), CCL4 (MIP-1β), CCL11 (eotaxin), CCL17 (TARC), CXCL8 
(IL-8), and CXCL10 (IP-10) was used.  The results were that frailty was significantly 
correlated (p<0.002) with immune activation markers IL-6, soluble CD14, and soluble TNF 
receptor 2 (TNFR2), in frail HIV+ men compared to non-frail HIV+ men (7).  CRP levels 
were almost 50% higher levels in HIV+ frailty+ men (p<0.002) than in HIV+ frailty− men, 
even after adjustments were made to factor donor characteristics (such as BMI and 
smoking), and comorbidities.  Most of these elevated markers are produced by activated 
monocytes or macrophages, suggesting that these cells play a role in the inflammation seen 
in HIV+ frail men. 
 
Another study found that frailty was associated with increased levels of activated CD8 T 
cells (expressing CD38 and HLA-DR) and serum IL-6 in HIV+ people (46).  In another 
study, frailty was significantly associated with higher IL-6 and soluble TNF receptor 1 
(TNFR1) levels (47).  Finally, in a third study a strong correlation was found between the 
CD4+ IL-2 response to CMV peptides and serum IL-6 in HIV− non-frail people, and this 
response was predictive of the development of frailty (8).  Specifically, HIV− nonfrail 
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donors in the highest tertile of CD4 IL-2 responses to CMV developed frailty at a 
significantly faster rate than those in the lower 2 tertiles; this relationship, however, was not 
found for HIV+ nonfrail donors.  This study is discussed in greater detail in section I.E. 
 
 CMV Infection D.
This project focused on the role of CMV infection in inflammation because, nearly all elderly 
adults are CMV seropositive (CMV+), and 90% or more of HIV+ people are also CMV+.    
There is also a huge T cell response to CMV (48), and this response had recently been 
shown to correlate with systemic inflammation as measured by serologic and cellular markers 
of immune activation (7).  As discussed earlier in the chapter, inflammation is common to 
both HIV infection and the normal aging process.  CMV causes chronic inflammation, 
making it an excellent candidate for causing, or at least contributing to, the inflammation 
seen in HIV infection and aging.  This section provides background information on CMV, 
its replication cycle and gene expression, the immune response to it, including inflammation, 
and finally the relationship between CMV, HIV infection, and aging. 
 
1. Epidemiology of CMV Infection  
Although CMV is found around the world and its prevalence increases with age, the 
distribution of CMV varies across the world.  In developing countries, CMV infection is 
acquired earlier in life, in contrast with the United States and Europe, where it is more 
prevalent among lower socioeconomic groups, especially in immigrant communities from 
developing countries (49).  CMV infection is spread by exposure to infected bodily fluids, 
with mucosal epithelium the most common site for primary infections.  CMV can also be 
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transmitted from a mother to her fetus during pregnancy, by crossing the placenta.  
Congenital infections can be very severe and can cause life-threatening cytomegalic inclusion 
disease (CID) (50).  The risk to fetuses is significant because CMV prevalence is slightly 
higher in women of childbearing age than in men of a similar age (51).   
 
2. Genome and Virion Structure of CMV 
CMV is the largest virus that causes human disease.  It is a member of the herpesvirus family 
and has a DNA genome 230kb long with over 750 identified protein-encoding open reading 
frames (ORFs) (52), as shown in Figure 1.3.  The CMV genome is composed of unique long 
(UL) and unique short (US) regions that are flanked by terminal and internal repeat 
sequences.  These repeat sequences contain genome cleavage and packaging signals that 
allow isomerization of the viral genome during replication (53).   
 
The CMV virion particle is 230nm in diameter (54) with a structure that is characteristic of 
other herpesviruses.  It has a DNA core inside a highly-stable 130nm icosahedral capsid, 
which is larger than that of other herpesviruses to accommodate CMV’s large genome.  The 
capsid is surrounded by an envelope, which contains viral glycoproteins to control 
attachment and entry into cells (50).  The capsid is composed of four core proteins that are 
essential for CMV replication (55).  The DNA genome is contained inside the nucleocapsid 
along with two virion RNAs (50).  The tegument, composed of 32 virus-encoded 
phosphorylated proteins, encloses the nucleocapsid.  The tegument is surrounded by a lipid 
bilayer envelope originally derived from the endoplasmic reticulum (ER)-Golgi intermediate 
compartment of the host cell, which is modified by the insertion of virus-encoded 
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glycoproteins (50).  The envelope glycoproteins gB, gH, gL, gM, and gN have essential 
functions in the replication of viral DNA and are the targets for neutralizing antibodies (gB 
will be discussed in detail in section I.D.3) (50).  Virion proteins also play an important role 
in cell entry, egress, and cell tropism.   
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Figure 1.3.  The Genomic Arrangement of CMV (from (56)). 
The key ORFs in the 230kb genome (56).  The green arrows represent ORFs, red arrows 
designate ORFs unlikely to encode a polypeptide.  UL= Unique long sequences.    
US= Unique Short sequences.  Rectangles superimposed on the line represent the sequence-
identify terminal repeats.  Each mark on the sequence line represents 1,000 bp. 
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3. The Replication Cycle of CMV 
As a result of its large genome, CMV has a replication cycle that takes 48 to 72 hours from 
viral entry to the final stages of maturation and progeny release (50).  The first genes to be 
expressed (within minutes after infection of permissive cells) are immediate-early (IE) genes.  
These are followed by delayed early (DE) and then late (L) genes, expressed 24 to 36 hours 
post-infection.  Figure 1.4 shows the key viral-host interactions that determine whether the 
virus will enter a lytic or latent phase of replication (57).  The sequential expression of the 
IE, DE, and L genes is highly regulated (58).  Figure 1.5 depicts the key viral proteins 
involved in the various stages of the CMV replication cycle (50). 
Figure 1.4.  Key Viral-Host Interactions to Determine Either Viral Lytic (Productive) 
Replication or Latency (from (57)).   
Signaling pathways are critical for establishing cellular environments for replication or 
latency.  US28, a viral chemokine receptor homolog, functions in both lytic and latent 
phases.  US28 activates IL-6/JAK/STAT3 signaling.  IE1 is essential for lytic replication.  
Cells infected with latent CMV upregulate PI3K or MAPK/ERK activation, leading to 




Figure 1.5.  CMV Replication Cycle (from (50)). 
Key viral proteins involved in the CMV replication cycle are shown, including gB, which is 
important for attachment, and IE1, which is essential for viral replication. 
 
 
i. Immediate Early Gene Expression 
IE gene expression is controlled by the major IE promoter (MIEP) that activates 
transcription of IE1 (p72) and IE2 (p86).  The MIEP regulates transcription by initiating 
viral gene transcription immediately after viral entry into permissive cells and by repressing 
transcription during latency (60) (see section I.D.6 for more on latent CMV).  Chromatin 
remodeling by histone acetyl transferases (HATs) and demethylases positively regulate MIEP 
expression.  Conversely, chromatin remodeling by histone deacetylases (HDACs) and 
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methyltransferases negatively regulate MIEP expression (61).  Tegument proteins pp71 
relieve initial HDAC-mediated repression of the MIEP, allowing the initiation of IE gene 
transcription (62).  By suppressing HDACs, MIEP proteins IE1 and IE2 play an active role 
in chromatin remodeling and continuing gene expression, and viral replication (60).  During 
latency (as discussed in section I.D.7), the MIEP region remains unmethylated due to CPG 
suppression, preventing IE transcription and viral replication (63).   
 
IE1 and IE2 result from alternative mRNA splicing of major immediate early genes (MIE), 
UL123 and UL122, respectively (64).  IE1 and IE2 are responsible for initiating productive 
viral genome replication by regulating the MIEP, and also suppresses the immune response, 
promoting the survival of the virus inside the cell.  IE1 associates with and disrupts nuclear 
domain 10 (ND10) (also known as promyelocytic leukemia protein (PML) bodies) (65), 
inhibiting HDACs that also interact with ND10 and enabling MIEP gene expression as well 
as DE and L gene transcription (66).  IE1-deficient viruses are unable to replicate efficiently 
due to the inability to inactivate HDACs and activate DE gene expression (61).  These 
replicative-deficient viruses are still able to disrupt ND10, suppress interferon response, and 
initiate DNA replication (67). 
 
ii. Delayed Early and Late Gene Expression 
DE gene expression peaks between 8 to 12 hours post-infection but continues through to 
24-hours post infection (h.p.i) (68).  DE genes are vital for viral DNA synthesis, and their 
loss significantly impairs viral replication (69).  The expression of UL54, a CMV-encoded 
DNA polymerase, starts around 8 h.p.i.  And remains constant throughout the L phase (50).  
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Other DE genes regulate the expression of other viral genes, which is important for efficient 
viral replication. 
 
The L phase of replication is considered to begin 24 h.p.i.  L gene proteins control the final 
stages of viral maturation, including capsid maturation, DNA encapsidation, and the exit of 
the virion from the cell (70).  One of the key genes expressed during the L phase is UL55-
coded glycoprotein B (gB), a highly-conserved envelope protein that is important for 
attachment and entry and is a major target for neutralizing antibodies (50).  It forms a trimer 
on the envelope surface that enables fusion and attachment with the cell membrane, 
allowing entry into the cell.  Cellular receptors for gB are unknown but may include cell 
surface integrins such as α2β1, α6β1, and αvβ3 (71) that are present on all cells, and the 
epidermal growth factor receptor (EGFR) on monocytes (72).  As the virion matures, gB is 
cleaved to create a 116 kd surface component that is bound to a 55 kd transmembrane 
component (50).  Antibodies to these domains can prevent viral binding and entry into cells, 
and soluble gB has been shown in human trials to elicit protective immunity (73). 
 
4. The Immune Response to Primary CMV Infection 
Primary CMV infection in peripheral tissues triggers a strong innate immune response with 
activation of natural killer (NK) cells and then an adaptive response that includes a diverse 
antibody and TEM response (74).  NK cells play a key role in controlling and fighting CMV 
infection by killing CMV-infected cells and by producing type I IFN, as illustrated by the 
rare people who lack NK cells and are extremely susceptible to multiple herpesvirus 
infections (75).  The important role of NK cells in fighting CMV is further highlighted by 
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the significant increase in CD56dim NK cells in the blood of healthy CMV-infected people 
over 60 years old (76).  NK cells also produce IL-22, which recruits neutrophils that 
contribute to control of the virus (77).  Initial IFN production by splenic stromal cells occurs 
10- to 12 h.p.i and relies on signaling by lymphotoxin αβ, which is produced by B-cells (78).  
IFN is subsequently produced by both plasmacytoid dendritic cells (DC) and conventional 
DC, which also produce high levels of IL-12 and IL-18, which together activate NK cells 
and prime the adaptive immune response (79).  In addition to NK cells, mast cells activated 
within hours of infection produce chemokines that recruit CD8+ T cells to the site of 
infection (80). 
 
5. The Immune Response to Persistent CMV Infection and Chronic 
Inflammation 
Once the initial infection is controlled, primarily by the innate immune system, CMV 
infection enters a persistent phase within infected tissue, where it may persist for months or 
years.  Here, the adaptive immune response plays an important suppressive role.  The 
expansion of effector T cells is sufficient to control the primary CMV infection in peripheral 
tissues.  A broad CD4 and CD8 T cell response accounts for up to 10-20%, or even more, 
of all circulating T cells in CMV-infected individuals, and it is this response that will 
eventually contract to generate a stable memory pool (48).  Sylwester et al. tested the T cell 
responses to many thousands of CMV peptides covering more than 150 ORFs, and 
demonstrated that there are specific T cell responses to most or all of them (48).  The 
breadth of the T cell response to CMV has also been shown in both HIV− (48) and HIV+ 
(81) people. 
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Such a large expansion of CMV-specific T cells leads to a net reduction in the diversity of 
the overall T cell pool, which compromises immune function (82).   
 
A subset of the primed TEM cells, comprised of “inflationary memory” cells, does not 
contract but rather can expand due to the persistence of viral antigens (82).  The expansion 
of CMV peptide-specific TEM cells can be very high in some people, with over 20% specific 
for a single antigen in some cases (83).  Inflationary memory cells often lack one or both of 
the co-receptors CD27 and CD28 (84) and express high levels of NK cell receptors, such as 
CD57 and KLRG1, along with the effector molecules perforin and granzyme B (85).  This 
TEM subset is maintained by a small population of CD27hi CD8 central memory T cells and 
is dependent on the initial dose of viral inoculum (86).  These inflationary memory cells also 
do not show typical signs of cell exhaustion, despite their continued exposure to CMV 
antigens.   
 
The persistence of inflationary memory cells may be due to expression on CMV-specific 
CD8+ T cells of molecules normally associated with NK cells, such as CD56 and killer-cell 
immunoglobulin-like receptors (KIRs) (82).  CD45RA, more often expressed on naïve T 
cells than memory cells, is also more highly expressed on these CMV-specific CD8 T cells, 
and may also contribute to the long-term survival of these cells (87).  The high frequency of 
oligoclonal CMV-specific CD8+ T cells indicates that extensive clonal expansion and 
selection have occurred, often with only a few epitope-specific clones dominating (88).  Cells 
that have reverted to CD45RA expression have high-avidity T cell receptors (TCRs) (89), 
which means they will bind more strongly with antigens and enable the cells to be more 
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likely to survive.  The survival of these T cells causes clonal diversity to decrease over time, 
leading to an increase in high-avidity CMV-specific CD8 T cell clones (90).   
 
As CMV-specific CD8+ T cells expand in CMV+ people, the number of CMV-specific 
CD4+ cells also increase with age with a more terminally-differentiated phenotype (91).  The 
priming of CMV-specific CD8+ T cells requires CD28-mediated co-stimulation, but CD28 
is not essential for memory inflation (82).  CD27 binding to CD70 (92), as well as the co-
stimulatory molecule OX40 (93), are important for both CD8 priming and also for memory 
expansion.  IL-2 helps the differentiation of effector T cells during the priming process.  IL-
2 may be produced by CD4 or CD8 T cells and in addition to antigenic stimulation is 
required for CD8 memory cell inflation (82). 
 
CMV also induces a strong antigen-specific antibody response.  Immunoglobulin (Ig) G 
levels rise throughout CMV infection during the persistent stages and seem to plateau as the 
virus is controlled (74).  IgM levels drop significantly after the initial primary infection is 
cleared (94).  Despite the strong antibody response to CMV by B cells, immune control of 
CMV is no different in mice lacking B cells (95).  This indicates that T cell responses are 
more important for control of human CMV infection that antibody levels. 
 
6. Mechanisms Used by CMV to Evade the Host Immune Response 
CMV modulation of the host immune response includes altering pathogen receptor 
signaling, inhibiting cytokine and interferon activation, and preventing cell death to ensure 
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that virions mature within the infected cell (as shown in Figure 1.6).  NF-κB activation 
occurs immediately after exposure to viral particles and again 24-hours post infection, in 
response to factors such as IFN and TNF, which are a result of the primary response.  
Cytosolic DNA censors (ZBP1) activate interferon regulatory factor-3 (IRF3) (96) and  
NF-κB (97) resulting in pro-inflammatory cytokine (IFNγ and TNF) production.  Viral 
proteins made during infection can limit the impact of the IFN response on host cells.  For 
example, IE1 forms a complex with STAT1 and STAT2 to prevent its binding to IRF9, 
which results in decreased activation of IFN-responsive promoters (98).   
Figure 1.6.  CMV and Immune Interactions During Lytic Infection (from (99).   
CMV viral proteins mediate evasion of the host immune response.  This evasion includes 
inhibiting the IFN response and preventing T- and NK cell activation and recognition and 






7. The Latent Phase of CMV Infection 
Latent CMV persists in specific cells and tissues, where it exhibits restricted viral gene 
expression and no viral production.  Latent virus has been detected in CD34+ myeloid 
progenitor cells that reside in the bone marrow, which provide a reservoir of virus that is not 
eliminated by the host (100).  These progenitor cells can differentiate into macrophages and 
dendritic cells where the virus subsequently can be reactivated.  Presence of CMV in these 
long-lasting cells and progenitors, which can differentiate into macrophages, enables the 
virus to reside in all tissues throughout the host.  Latently-infected cells are rarely detected in 
the peripheral blood (101).  Studies have suggested that, during latency, the frequency of 
viral genome-positive cells in the peripheral blood ranges from 10−4 to 10−5 PBMC, with 2 to 
15 CMV genome copies per cell (101).  During latency the viral genome is maintained in an 
episomal form in the nucleus.   
 
Most CMV proteins are suppressed during latency (as shown in Figure 1.7), but those that 
are expressed have an important role in maintaining viral latency and preventing recognition 
by T cells.  Latent proteins LUNA (102), UL138 (103), US28 (104) and vil-10 (105) are the 
only proteins that have been detected during latent infection.  They can be recognized by 
CD4+ T cells that secrete immunomodulatory cytokines IL-10 and transforming growth 
factor-beta (TGFβ), rather than IFNγ (106).  The importance of IL-10 in the maintenance of 
latent CMV is highlighted by the CMV-encoded vil-10 homolog that is expressed during 
latent infection (107).  CMV-encoded IL-10 suppresses the immune system by 
downregulating major histocompatibility complex (MHC) class I and II (108) and preventing 
DC maturation and function (109).  IE1 expression is repressed by the MIEP but may be 
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reactivated by transcriptional activators such as NF-κB or by differentiation and activation of 
the infected myeloid cells by pro-inflammatory cytokines (110).  Cells latently infected with 
CMV can avoid apoptosis by upregulating the cellular anti-apoptotic protein MCL-1 and by 
dysregulating the ERK-MAPK signaling pathway in CD34+ cells (111). 
Figure 1.7.  CMV Replication During Lytic and Latent Infection (from (99)).   
In latently-infected cells there is targeted suppression of lytic viral gene expression and 
expression of a few latently-associated genes detectable, including LUNA, UL138, and US28.   
 
 
8. CMV in Aging 
The interaction between CMV and the immune response during aging may result in an 
inability to control replication of the virus.  This was suggested by a greater amount of CMV 
DNA in the urine of older people as compared to that of young people, and by the reported 
increase of latent CMV genomes in CD14+ monocytes in people over 70 years old (112), 
although these findings have yet to be independently corroborated.  High levels of CMV-
specific IgG are associated with aging, increased mortality, and cardiovascular disease (49).   
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Latent CMV is associated with the accumulation of a large number of TEMRA CD8+ 
CD27- CD28- CCR7- CD62L- CD57+ CD45RA+ T cells with reduced functionality and 
proliferative capacity (113).  The accumulation of CMV-specific CD8+ TEMRA may be due 
to chronic antigenic stimulation by the latent virus (34).  Latency may involve intermittent 
gene activation that results in incomplete reactivations, causing intermittent antigenic activity 
that can stimulate clonal expansion of CMV-specific T cells.  CMV has been shown to be 
associated with HIV infection and aging and with the chronic inflammation present in 
people suffering from these conditions (8).  The exact role that CMV plays in the 
pathogenesis of the inflammatory response seen in HIV infection and aging is an important 
question that remains to be answered. 
 
 Objectives of this Project E.
The increasing number of people living longer with HIV since the introduction of HAART 
(1) has led to a rise in HANA conditions, such as frailty.  Frailty has been shown to be a 
good predictor for the development of serious chronic conditions, such as acute illness, 
cognitive decline, chronic inflammation, and mortality (39).  Chronic inflammation can cause 
cell and tissue damage and immune dysregulation and is commonly seen in people who are 
HIV+ and frail.  Inflammatory markers, such as TNF, IL-6, and CRP, are elevated in people 
who are both HIV+ and frail (7). 
 
Persistent viral infections such as CMV can also cause chronic inflammation.  Nearly all 
HIV+ individuals are also co-infected with CMV, and CMV has been associated with a 
higher risk of frailty and mortality in older women (114).  CMV seroprevalence increases 
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with age and also distorts the immune response.  By considerably altering the T cell 
repertoire, up to 20% (and in some cases higher) of CD4+ and CD8+ T cells are CMV-
specific, and the resultant net-shrinking of the T cell pool can compromise immune 
function.   
 
Whether CMV is responsible for the chronic inflammation seen in HIV+ individuals and in 
frail people is an important question that has not been answered.  Inflammation in aging is a 
problem that affects people who are both HIV− and HIV+.  As more people live longer 
with HIV infection, understanding the aging process and associated conditions, such as 
frailty, will become even more critical.  Improving our understanding of the role CMV plays 
in chronic inflammation may help identify new possibilities for alleviating chronic 
inflammation.  This includes people with HIV infection who are at risk of developing frailty 
and other manifestations of the normal aging process, such as atherosclerosis. 
 
As discussed earlier in this chapter, previous studies have shown that people with HIV 
infection have a high CMV seroprevalence, which is associated with a higher risk of frailty; 
they also have very strong T cell responses to CMV peptides (115), and higher prevalence of 
frailty at earlier ages than HIV− people (45).  However, the role CMV infection plays in the 
chronic inflammation seen in aging in both HIV+ and HIV− people is poorly understood.   
 
A recent study by Margolick et al. evaluated the relationship between T cell responses to 
CMV peptides, systemic inflammatory markers, and frailty in HIV-infected and -uninfected 
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men from the Multicenter AIDS Cohort Study (MACS) (8).  MACS is an ongoing 
longitudinal study of HIV infection in MSM, where participants provide blood samples on a 
semi-annual basis (116, 117).  At each visit, HIV status, health indicators, and since 1997 
frailty status for the Fried FP are recorded for each participant (more details on the MACS 
can be found in the Methods).  Most HIV+ participants have received HAART and have 
suppressed their HIV viremia to undetectable levels, greatly reducing or eliminating the 
effects of HIV viremia.  Using CMV peptide pools that covered 19 CMV ORFs (UL28, 
UL32, UL36, UL48, UL55, UL82, UL83, UL86, UL94, UL99, UL103, UL122, UL123, 
UL151, UL153, US3, US24, US29, and US32), the number of CD4 and CD8 T cells that 
produced pro-inflammatory cytokines in response to CMV antigens was measured in 42 
MSM.  The numbers of responding cells were analyzed by HIV and frailty status, first for the 
study group as a whole (n=42), followed by subgroups stratified by HIV status (20 HIV−, 
22 HIV+), frailty status (21 non-frail, 21 frail), and finally by both HIV and frailty status: 
HIV−/frailty− (n=10), HIV+/frailty− (n=11), HIV−/frailty+ (n=10), HIV+/ frailty+ 
(n=11). 
 
All of the men in that study had positive CD4 and CD8 T cell responses to at least some of 
the CMV peptides tested.  The frequency of TNF-producing T cells was higher in HIV+ 
than HIV− individuals.  The proportion of CMV responsive T cells producing IL-6 was 
higher in frail compared to non-frail men.  Stratification by HIV infection or frailty status 
showed significant correlations that were absent when the overall study population was 
evaluated.  The HIV+ non-frail group (n=11) showed strong and significant positive 
correlations between the total number of CD4 T cells producing either IFNγ or TNF with 
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the number of activated CD4 T cells.  The frequencies of CMV-responsive T cells that 
produced TNF, IL-6, IL-2, and IFNγ were associated with the presence or onset of frailty.  
The HIV− frail group showed significant correlations between total IFNγ and TNF 
responses.  The HIV+ frail group also showed strong and significant correlations between 
the frequency of CD4 T cells producing TNF and the number of activated CD4 T cells, and 
also between the proportion of CD8 cells producing TNF and serum levels of CRP.  The 
frequency of IL-2-responsive CD4 cells significantly predicted the onset of frailty in HIV− 
non-frail men but not in HIV+ non-frail men (8).  These findings suggested that T cell 
responses to CMV may not only affect the chronic inflammation present in HIV-infected 
men but may also be a predictor of frailty in HIV− men. 
 
While all of the men in that study responded to CMV peptides, CMV presence in those 
studied was not investigated.  This left unanswered an important question: do differences in 
the amount of CMV in the circulation account for the differences in the number of CMV-
responsive T cells in the circulation?  The very low expression of CMV proteins while the 
virus is latent could prime the immune system, leading to an increase in the number of 
CMV-responding T cells in the circulation. 
 
That study raised important questions, which this project aimed to investigate.  Specifically, 
this project sought to determine whether the presence of CMV in the blood affects the 
inflammatory response by T cells to CMV peptides.  By detecting and quantifying any CMV 
DNA present and correlating this with known (i.e., already measured) T cell responses to 
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CMV peptides and antigens, this project sought to improve the understanding of the role 
CMV plays the pathogenesis of chronic inflammation. 
 
 Aims and Hypotheses F.
Based on the previous studies discussed above, this project focused on understanding 
whether there is a relationship between the detection of CMV in PBMC and the T cell 
responses to CMV.  The first step was to detect CMV in PBMC.  Previous studies had 
detected CMV in PBMC using nested PCR (118) which is a sensitive method but is not 
quantitative.  The development of droplet digital PCR (ddPCR), which was purported to be 
a highly sensitive and also quantitative technique, led to its use in this project.  Recently, 
ddPCR had been used to detect CMV in blood and semen (112, 119) but at the start of this 
project, a sensitive ddPCR assay needed to be developed and then applied to the appropriate 
human biological specimens.  Therefore, the specific aims and hypotheses of the project 
were as follows:  
 
Aim 1 
To validate the amount of CMV DNA in PBMC using a novel ddPCR assay.  A highly 
sensitive assay was required to enable the detection of CMV DNA in cells where CMV was 
not actively replicating.  The inability of other PCR methods to reliably detect and quantify 
CMV indicated that CMV DNA was only present in a limited number of cells during the 
latent phase of CMV infection.  While there are other sensitive methods to detect CMV 
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DNA, they are not quantitative.  Once validated, the assay was used to detect and quantify 
CMV DNA in a variety of human specimens. 
 
Hypothesis 1 
CMV DNA can be detected and quantified in PBMC.  The improved sensitivity of the 
ddPCR assay may detect CMV DNA better than other assays such as nested PCR.   
 
Aim 2 
To evaluate the relationship between the detection of CMV DNA and the frequency of 
CMV-responsive T cells.  The detection of CMV DNA in PBMC was compared with T cell 
responses to CMV using available data from a previous study.  The aim includes determining 
whether HIV and frailty status affects the correlation of CMV DNA detected with the pro-
inflammatory cytokine responses to CMV peptide stimulation. 
 
Hypothesis 2 
a) The quantity of CMV DNA, and specific CMV genes detected, is correlated with the 
frequency of CMV-responsive T cells; and  






 Study Population and Samples A.
1. MACS-SHARE Cohort 
The SHARE is the Baltimore-Washington DC site of the MACS.  MACS was established in 
1984 (116, 117) and is the nation’s largest and longest ongoing prospective study of the 
natural and treated history of HIV infection in MSM.  Conducted at four sites across the 
country (Baltimore, Chicago, Los Angeles, and Pittsburgh), MACS has collected biological 
and behavioral data, and stored biological specimens, from more than 7000 men.  MACS 
participants are about half HIV+ and half HIV−.  SHARE has followed about 1800 men.  
Participants in MACS and SHARE are evaluated semi-annually by laboratory analysis of 
collected blood samples, physical examinations, and analysis of questionnaires that include 
medical history, health services, and behavior.  Plasma, serum, and viable peripheral blood 
mononuclear cells (PBMC) are frozen and stored in liquid nitrogen at each semi-annual 
study visit.  HIV serostatus is recorded at each SHARE clinic visit.  Seropositivity is defined 
by a positive ELISA with confirmation by western blot.  Since 2007, the frailty status of each 
participant has been assessed at each semi-annual study visit, using the Fried frailty 
phenotype (FFP) (44); this phenotype is based on the presence of at least 3 of 5 criteria: 
weakness as measured by grip strength, low physical activity, slow motor performance 
measured by walking speed, exhaustion, and unintentional weight loss (39).  The criteria are 
assessed either by answers to a questionnaire or by measuring responses (i.e., walking speed 
is measured by the amount of time taken to walk 4m, and grip strength is measured with a 
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dynamometer).  In the early years of the study (1984-86), semen samples were also collected 
and stored. 
 
In this project, frozen PBMC collected as part of the SHARE study were obtained from the 
Johns Hopkins Bio-Repository.  These PBMC were used to validate the droplet digital PCR 
(ddPCR) assay, to detect and quantify CMV DNA, and to investigate the relationship 
between the detection of CMV DNA and inflammatory responses in individual donors.  In 
some experiments, freshly-isolated PBMC were used, and in others cryopreserved PBMC 
were used. 
 
2. Samples to Validate ddPCR Assay 
To detect and quantify CMV DNA, a ddPCR assay was used.  A series of experiments was 
conducted to determine the sensitivity and specificity of the ddPCR assay in detecting CMV 
DNA.  To determine the sensitivity of the ddPCR assay, a series of 10-fold serial dilutions of 
CMV AD169 genomic DNA (Advanced Biotechnologies, Eldersburg, MD) was used.  
Starting with a concentration of 1x104 copies/µl, the CMV DNA was diluted down to 0.1 
copies/µl. 
 
To ascertain the effectiveness of the ddPCR assay in detecting CMV DNA in cells, samples 
from donors who were known to be either CMV+ or CMV-seronegative (CMV−) were 
tested.  Human Foreskin Fibroblasts (HFFs) (obtained from Dr. Ravit Boger, JHU) were 
either uninfected or were infected with CMV (Towne strain from Dr. Boger) at a multiplicity 
of infection (MOI) of 1, 0.1, or 0.01, and DNA was harvested 72-hours post infection (h.p.i).  
0.05% Trypsin-EDTA (Thermofisher Scientific, Waltham, MA) was used to detach the 
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HFFs from the well.  The infected HFF were spun down at 300g x 5 minutes before being 
washed in 1 ml 1x Phosphate Buffered Saline (PBS) (Thermofisher Scientific).  After 
spinning the cells down again, the DNA was isolated from the cells as described later in this 
section. 
 
To corroborate the ability of the ddPCR to detect CMV DNA, DNA from PBMC whose 
donors were of known CMV serostatus (obtained from Dr. Sean Leng, JHU) were tested by 
both ddPCR and by nested PCR (as discussed in section III.C).  PBMC from 2 CMV+ and 1 
CMV− donors were tested by both methods. 
 
It has been suggested that CMV persists in monocytes (120).  To compare levels of CMV in 
monocytes and PBMC, fresh PBMC were used to isolate monocytes from 4 HIV+ 
participants.  PBMC from a SHARE clinic (which is held in the evenings) were held 
overnight at 4˚C in RPMI 1640 media (Thermofisher Scientific) with 10% fetal bovine 
serum (FBS) (Thermofisher Scientific) added.  The following morning the adhered 
monocytes were isolated as described later in this section.  
 
3. Cells Used to Detect and Quantify CMV DNA  
To quantify the levels of CMV DNA in CMV+ and CMV− donors, PBMC were obtained 
from 8 CMV+ and 8 CMV− participants from the Women’s Health and Aging Studies 
(WHAS) II (121) (PI Dr.  Sean Leng, JHU), which studies the immune response to influenza 
immunization.  These participants had been tested for CMV antibody and had multiple 
aliquots of PBMC cryopreserved in liquid nitrogen.  The average ages of the CMV+ and 
CMV− participants were 85 and 85.9 years, respectively.  In addition, by nested PCR, CMV 
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DNA had been detected in the CMV+ participants but not in the CMV− participants 
(unpublished data). 
 
To maximize the likelihood of finding PBMC that contained detectable CMV DNA and thus 
could serve as a positive control for the ddPCR assay, PBMC from HIV+ SHARE 
participants obtained before the advent of highly-active antiretroviral therapy (HAART) 
were tested by ddPCR.  The rationale for testing these participants was that because they had 
uncontrolled HIV viremia and low CD4 T cell counts, they would be likely to have more 
CMV DNA in their PBMC than virologically-suppressed participants.   
 
For the same reason, semen obtained from 20 HIV+ SHARE participants early in the study, 
before the availability of HAART, was studied.  Previous studies have shown that CMV is 
found in high concentrations in the semen, as it can be sexually (119) transmitted.  The 
semen samples were thawed at room temperature before the DNA was isolated along with 
the DNA from PBMC, as described later in this section. 
 
Also studied were PBMC from 36 SHARE participants who had recently been studied by 
Margolick et al. (8) to investigate the relationship between the T cell responses to CMV 
antigens and the systemic inflammatory response, as described in section I.E of the 
Introduction.  These participants had already been characterized by their HIV status (19 
HIV+ and 17 HIV−) and their frailty status (18 frail and 18 non-frail).   
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 Laboratory Methods and Materials B.
1. Thawing Cells 
Frozen PBMC were thawed in a 37˚C water bath.  When only a small piece of ice remained 
in the cryovial, 13 ml warm RPMI 1640 media supplemented with 50% FBS was 
immediately added in a dropwise fashion as follows: 1 ml, 2 ml, 4 ml, and 6 ml, waiting 1 
minute between each round of media.  Cells were then centrifuged at 300g for 10 minutes 
and washed using RPMI 1640 with 10% FBS.  Cells were counted using a hemocytometer, 
using trypan blue exclusion to determine the number of viable cells.  The number of viable 
cells recovered from thawed PBMC that had been stored in the SHARE repository was at 
least 80% of the total number of cells frozen.   
 
2. Monocyte Isolation from PBMC 
As described above (section II.B), PBMC from HIV+ SHARE participants were used to 
isolate monocytes.  From each participant, 20x106 PBMC in RPMI 1640 media 
supplemented with 10% FBS and 1% Penicillin/Streptomycin (Thermofisher) were divided 
into (a) 5x106 cells, used to isolate DNA from total PBMC, and (b) 15x106 cells, used to 
isolate monocytes.  For the latter, 1% autologous serum was added to the media, and the 
cells incubated in 3 wells of a 6-well plate (Thermofisher) overnight at 37˚C.  The following 
morning, the cells were examined under a microscope, and adherent monocytes were 
identified by their morphologic appearance.  The nonadherent cells, which were detached in 
the media, were aspirated along with the cell culture media, and the adherent cells were 
washed with 1% PBS (Thermofisher).  The adherent cells were removed from the well using 
a cell scraper, and the DNA was isolated as described below. 
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3. DNA Isolation 
DNA was isolated from cells and semen using the QIAamp DNA mini kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s protocol.  No more than 10x106 cells or 200 µl 
semen were used from any given sample.  DNA was eluted from the QIAamp mini spin 
columns in 100 µl H2O, and the DNA concentration and purity were measured using a 
nanodrop. 
 
 CMV Detection and Quantification C.
1. Overview of PCR 
Polymerase chain reaction (PCR) is the amplification of a specific target sequence of DNA 
through repetitive cycles of denaturing, elongation, and annealing.  Using forward and 
reverse primers that are complementary to the target sequence and a DNA polymerase that 
elongates DNA by adding nucleotides to the 3’ end (e.g., Taq polymerase), the target 
sequence is amplified many times.  Commonly-used PCR methods such as real-time PCR 
(RT-PCR) and nested PCR have limited sensitivity and are not quantitative.  Rather, they rely 
on the generation of a standard curve to quantify the amount of target sequence detected.  
Nested PCR is a more sensitive PCR assay than RT-PCR because it uses two separate 
rounds of PCR to detect the target sequence, where the second round detects sequences 
found only within the PCR product of the first round.  This makes nested PCR more 
sensitive than RT-PCR, but it is still not a quantitative assay. 
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ddPCR differs from the other PCR techniques by mixing the sample with oil to make 20,000 
nanoliter-sized droplets in such a way that the majority of droplets contains only one 
molecule of DNA.  PCR amplification of the template DNA will occur in each droplet, and 
lack of competing DNA molecules provides a lower background to the assay, thus making 
ddPCR highly sensitive.  Most DNA droplets containing the target DNA will fluoresce due 
to primers or probes binding to the specific target DNA sequence.  Forward and reverse 
primers use the double-stranded DNA (dsDNA) binding dye EvaGreen to fluorescently 
label the target DNA (Figure 2.1).  Fluorescently-labeled probes rely on Taq man hydrolysis 
to cleave the fluorescent reporter (e.g. 6-Carboxyfluorescein (FAM) or hexachlorofluorescein 
(HEX)) at the 5’ end, away from the quencher at the 3’ end of the probe (Figure 2.2).  The 
reporter then becomes fluorescent, and therefore detectable, because it is no longer in close 
proximity to the quencher.  Because the potential fluorochromes has been incorporated into 
the nucleotides, the magnitude of the fluorescent signal is proportional to the amount of 
amplified product in the sample.  The number of fluorescent droplets (i.e., droplets 
containing the target DNA) is read by the droplet reader, and the number of DNA copies/µl 
is quantified, as described below.  The ability of the droplet reader to count the number of 
positive and negative fluorescent droplets in a known volume allows the quantification of 
DNA (copies/µl) without the need for a standard curve.   
 
 
2. ddPCR: Specific Methods  
i. Controls  
CMV AD169 genomic DNA was used as a positive control and to determine the sensitivity 
of the ddPCR assay.  Negative controls were a no template control (NTC), DNA isolated 
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from CMV-uninfected HFFs, THP-1 cells, mouse tail DNA, or PBMC from a CMV− 
leukopak.  The CMV− serostatus of the leukopak had been previously determined by CMV 
ELISA in the Pathology Dept. at Johns Hopkins Hospital.  These negative controls were 
used to determine the background fluorescence levels of the ddPCR assay.  The RPP30 
gene, of which there are two copies in each cell, was used as a housekeeping control and to 
allow determination of the exact number of cells contained in each sample tested. 
 
ii. Primers 
PCR was set up containing DNA, the probe or primer, and the appropriate supermix for 
either probes or primers.  Forward and reverse primers to IE1 (from collaborator Dr. Leng), 
UL54 (IDT, Skokie, IL) and UL55 (IDT, Skokie, IL), were designed to bind to specific 
sequences in their respective CMV genes (sequences in Table 2.1).  The same was done for 
RPP30 primers.  The reaction mix was made up of 10 µl of 2X EvaGreen supermix (Bio-
Rad, Hercules, CA) that contained the EvaGreen dye.  A total of 50 ng DNA and 1 µl of 5 
µm forward and reverse primers were used per sample.  3 µl water brought the total reaction 
mix up to 20 µl per sample (Table 2.1)  
 
Figure 2.1.  Mechanism of Fluorescence by the Primers (from (122)).  
The primers use EvaGreen, an intercalating double-stranded DNA (dsDNA) binding dye, 






The FAM-labeled gB probe was obtained from collaborator Dr.  Sara Gianella (UCSD).  The 
reaction mix was made up of 10 µl of supermix for probes (Bio-Rad, Hercules, CA) that 
contained the Taq polymerase, along with 1 µl of gB FAM probe.  1 µl of RPP30 HEX 
probe (Bio-Rad, Hercules, CA) was included in the reaction mix as a housekeeping control.  
5 µl of DNA was included in the reaction mix (Table 2.2).   
 
Figure 2.2.  Mechanism of Fluorescence by the Probe (from (122)).   
The labeled probe binds to the target sequence amplified by the primer set.  During the 
extension cycles, the 5’ fluorescent reporter is cleaved, allowing it to fluoresce as it is no 






Table 2.1.  Primer and Probe Sequences  
Primers 
IE1 forward primer TCTGCCAGGACATCTTTCTC 
IE1 reverse primer GTGACCAAGGCCACGACGTT 
UL54 forward primer ACGATTCACGGAGCACCAG  
UL54 reverse primer GCTGACGCGTTTGGTCATC  
UL55 (gB) forward primer GCGGTGGTTGCCCAACAGGA   
UL55 (gB) reverse primer ACGACCCGTGGTCATCTTTA 
RPP30 forward primer GATTTGGACCTGCGAGCG  
RPP30 reverse primer GCGGCTGTCTCCACAAGT 
gB probe 
set 
gB probe set forward primer AGGTCTTCAAGGAACTCAGCAAGA  
gB probe set reverse primer CGGCAATCGGTTTGTTGTAAA  
gB FAM probe AACCCGTCAGCCATTCTCTCGGC with 
5’FAM reporter and internal ZEN and 3’ 
IBFQ quenchers 
 RPP30 HEX probe Bio-Rad #10031255 
Primers from IDT, Skokie, IL and CMV FAM probe from Dr.  S Gianella, UCSD  
 
Table 2.2.  Primers vs. Probes ddPCR Assay Preparation 
Probes Primers 
5 µl DNA (no more than 500 ng total DNA) 5 µl total DNA (10 ng/µl) 
10 µl supermix for probes (no dUTP) 10 µl 2X EvaGreen supermix 
1 µl CMV FAM probe 1 µl Forward primer (5um) 
1 µl RPP30 HEX probe 1 µl Reverse primer (5um) 





iv. Droplet Generation 
The ddPCR assay used water-oil emulsion to partition the DNA in the sample into 20,000 
nanoliter-sized droplets (Figure 2.3) using the Bio-Rad QX200 Droplet Generator (Bio-Rad, 
Hercules, CA).  20 µl of sample was added to the middle well of a droplet generator 
cartridge, and 70 µl of either droplet generator oil for EvaGreen or droplet generator oil for 
probes was added to the bottom well of the cartridge.  When the droplet generation was 
completed, 40 µl of droplets containing the template DNA were transferred to a 96-well 
plate and read on the droplet reader, as described below. 
 
Figure 2.3.  Droplet generation in ddPCR (from (122)) 
Single PCR sample partitioned into 20,000 nanoliter-sized droplets.  Based on the Poisson 
distribution, droplets are likely to only get 1 copy of the target sequence which will be 
detected above the background.  Any background fluoresce will be subtracted from the 





v. PCR Amplification 
PCR amplification was performed within each droplet on a thermal cycler.  ddPCR cycling 
conditions for the primers are shown in Table 2.3 and were as follows: initial enzyme 
activation at 95°C for 5 minutes; 40 cycles consisting of denaturation at 95°C for 30 seconds 
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followed by annealing and extension at 60°C for 1 minute; signal stabilization at 4˚C for 5 
minutes; and a final extension at 90°C for 5 minutes.   
 
Table 2.3.  Primer PCR Thermal Cycler Conditions 
 
Temp (˚C) Time Ramp rate Number cycles 
Enzymes reaction: 95 5 min 
2C/sec 
1 
Denaturation 95 30 sec 40 
Annealing/Extension 60 1 min 40 
Signal stabilization 
4 5 min 1 
90 5 min 1 
 
ddPCR CMV cycling conditions for the probe are shown in Table 2.4 and were as follows: 
initial enzyme activation at 95°C for 10 minutes; 50 cycles consisting of denaturation at 94°C 
for 30 seconds followed by annealing and extension at 54°C for 1 minute; and a final 
extension at 98°C for 10 minutes.   
 
Table 2.4.  Probe PCR Thermal Cycler Conditions 
 
Temp (˚C) Time Ramp rate Number cycles 
Enzymes reaction: 95 10 min 
2c/sec 
1 
Denaturation 94 30 sec 
50 
Annealing/Extension 54 1 min 
Signal stabilization 98 10 min 1 





vi. Droplet Reading 
After completion of the PCR, the droplets were read on the Bio-Rad QX200 Droplet Reader 
(Bio-Rad, Hercules, CA), which measures the fluorescence of each droplet and counts the 
numbers of fluorescent and non-fluorescent droplets.  These data were analyzed using 
QuantaSoft software (Bio-Rad).  A threshold that determined which droplets are positive 
(blue dots in figures) and which are negative (black dots) was manually set in each 
experiment, based on the level of fluorescence and the proportion of positive droplets 
obtained in the negative controls, to minimize the background fluorescence levels.  This 
threshold is shown as a pink horizontal line in the figures in the Results section.  CMV 
concentration was quantified by the QuantaSoft software using the following formula:  
 
where N is the total number of droplets, Nneg is the number of negative droplets, and Vdroplet 
is the volume of the droplet, calculated by the droplet reader as the droplets are read.   
 
vii. ddPCR Analysis 
Background (non-specific) fluorescence levels was subtracted from detected CMV-specific 
fluorescence.  Results were expressed as amount of DNA per million cells based on the cell 
number determined from copies of RPP30 detected in each sample  
 
3. Nested PCR 
125 ng DNA was used for the first nested PCR reaction followed by 5 µl of PCR product 
for the second round of nested PCR.  The IE1 primers used for the second round of nested 
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PCR were the same as those used for the detection of IE1 by ddPCR (Table 2.5).  The NTC 
and no primer controls (NPC) were used as negative controls.  The thermal cycler conditions 
that were used for the first round and second round of nested PCR are shown in Table 2.6 
and Table 2.7, respectively. 
 
Table 2.5.  Nested PCR Primers: Round 1 and Round 2 
Round 1 primer (forward) 5’-CAATACACTT CATCTCCTCGAAAGG-3’ 
Round 1 primer (reverse)  5’-ATG GAGTCCTCTGCCAAGAGAAAGATGGAC-3’ 
Round 2 primer (forward)* 5’-TCTGCCAGGA CATCTTTCTC-3’ 
Round 2 primer (reverse)* 5’- GTGACCAAGGC CACGACGTT-3’ 
* Round 2 primers are the same as the IE1 primers used in ddPCR 
 
Table 2.6.  Thermal Cycler Conditions Used for Nested PCR Round 1 
 
  
 Temperature (˚C) Time # of cycles 
Initial denaturation 95 3 min 1 
Denaturation 95 30 s 
40 Annealing 41.8  30 s 
Extension 72 1 min 
Final extension 72 10 min 10 
 12 5 min 5 
 47 
Table 2.7.  Thermal Cycler Conditions Used for Nested PCR Round 2 
 
 
4. CMV DNA Data Analysis 
To account for differences in the number of cells included in each well, the amount of CMV 
DNA was divided by the number of cells in the well.  To perform analysis of those with and 
those without detectable CMV DNA, the top 25% of specimens with detectable CMV levels 
were considered positive and compared to the lower 75% of specimens, which were 
considered not to contain CMV DNA.  Statistical significance of differences between those 
specimens with detectable CMV DNA and those without detectable CMV DNA was 
determined using a Mann-Whitney U test, with a p-value less than 0.05 considered 
significant.  Those specimens which were positive for CMV DNA and those without 
detectable CMV DNA were compared for each CMV gene analyzed (IE1, UL54, UL55, and 
gB).  This data was correlated with data from a previous study quantifying the frequency of 
T cells producing cytokines in response to CMV peptide stimulation (8).  The differences 
between the groups were measured for each cytokine produced (IFNγ, TNF, and IL-2) in 
response to each CMV peptide pool used for stimulation.  Initially analyzed as a whole 
group, the group was then stratified by HIV status (2 groups), frailty status (2 groups), and 
 Temperature (˚C) Time # of cycles 
Initial denaturation 95 3 min 1 
Denaturation 95 30 s 
40 Annealing 55 30 s 
Extension 72 1 min 
Final extension 72 10 min 10 
 12 5 min 5 
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then by both HIV and frailty subgroups (4 groups): HIV− frailty−, HIV+ frailty−, HIV− 
frailty+, HIV+ frailty+.  The Kruskal-Wallis test was performed to determine if the 
frequency of T cell responses to CMV peptides when CMV DNA was detected, showed 
statistically significant differences between the HIV and frailty subgroups. 
 
Spearman correlation coefficients were used to assess the correlation between results 
obtained using the CMV primers for UL55 DNA and the gB probe, since they measure the 
same CMV gene, to measure how accurately they measured presence of this gene in a donor.  
CMV levels measured for a donor using the UL55 primer were plotted against the CMV 
levels for the same donor using the gB probe.  A line of best fit was made between the 




 An Overview of the Approach A.
To determine whether CMV plays a role in inflammation, it was necessary to detect and if 
possible quantify the levels of CMV DNA and RNA, and evaluate how those levels correlate 
with markers for inflammation.  Measuring CMV RNA and protein levels would be an ideal 
way to measure these correlations.  However, in most of the population CMV is in a latent 
form that is not actively replicating, and the number of cells infected with CMV is very low.  
Due to these factors, I started by looking for CMV DNA before trying to detect RNA.  The 
ability to detect and quantify CMV DNA would establish which cells are infected with the 
virus and would permit analysis of possible links to explain the inflammation seen.   
 
Droplet digital PCR (ddPCR) was chosen as a method for analyzing CMV DNA, because it 
quantifies the amount of DNA per cell and had also been previously used to detect CMV in 
PBMC (112, 119).  By separating the genomic DNA into 20,000 nanoliter-sized droplets that 
each undergo amplification, ddPCR is very sensitive and good at detecting rare events.  
Using fluorescent dyes that intercalate with double stranded DNA (dsDNA) (e.g., 
EvaGreen) or fluorescently tagged probes (e.g., FAM or HEX) that bind to the target gene 
during the PCR, droplets containing the target DNA of interest fluoresce.  Droplets above 
the background level of fluorescence were considered positive, and using the Poisson 
distribution the relative numbers of droplets positive and negative for fluorescence allow 
calculation of the amount of CMV DNA detected in the specimen.   
 50 
 
The no-template control (NTC) contained both the forward and reverse primers and the 
master mix containing the polymerase but no DNA, and thus acted as negative control to 
measure background (non-specific) levels of fluorescence.  The background levels from the 
negative controls were subtracted from the results of the analyses containing DNA from 
CMV+ donors, to determine the amount of CMV DNA detected in a given specimen.   
 
To quantify the number of cells in each 20 µl well, RPP30, a housekeeping gene present at 2 
copies/cell in all specimens, was measured.  The amount of CMV DNA in each well was 
divided by the number of cells, to obtain the number of CMV DNA copies/106 cells. 
 
 Designing a ddPCR Assay to Measure CMV DNA B.
1. Validation of the ddPCR Assay  
As CMV DNA was expected to be at very low levels and in few cells, the first step was to 
establish the sensitivity and specificity of the ddPCR assay. 
 
i. Sensitivity of the ddPCR Assay  
To determine the sensitivity of the ddPCR assay to detect CMV, a standard curve was 
created using serial 10-fold dilutions of genomic CMV DNA from the AD169 strain of 
CMV.  The highest concentration of AD169 DNA was 1x104 copies/µl and the lowest was 
0.1 copies/µl.  5 µl of the standard was loaded in each 20 µl well.  NTC and Human 
Foreskin Fibroblasts (HFFs) not infected with CMV were used as negative controls, and 
CMV-infected HFF as a positive control. 
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The ddPCR results for this standard curve are shown in Figure 3.1a.  The NTC and CMV− 
HFF controls had 1 and 2 positive droplets, respectively.  The average of these values was 
considered the background level and was subtracted from the other samples.  All the 
droplets in the CMV-infected HFF well were positive.  This was because too much template 
DNA was present, so all the droplets were positive and the sample was oversaturated.  
Without negative droplets present in the sample, the number of DNA copies/µl cannot be 
calculated.  However, at lower concentrations of CMV DNA this was not a problem, 
because both positive and negative droplets were present.  Further, IE1 was detected from 
104 CMV copies/μl down to 1 copy of genomic CMV DNA.  The dilution with zero copies 
of CMV had the same number of positive droplets as the negative controls, suggesting that 
these droplets probably represented non-specific background rather than CMV DNA.   
 
The number of CMV DNA copies measured in each dilution was regressed against the 
expected number of CMV DNA copies (Figure 3.1b).  The R2 value of this regression was 
0.9987, indicating that the assay was highly linear and accurate, with very little variation from 
the expected values.  The sensitivity of the assay was determined as the smallest amount of 
template that was reliably detected.  In this case, the ddPCR assay detected 1 copy of 
genomic CMV DNA.   
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Figure 3.1. Standard Curve of Detection of CMV Genomic DNA by ddPCR.  
(a) IE1 CMV DNA primers were used to detect CMV DNA in a series of 10-fold serial 
dilutions of AD169 CMV genomic DNA from 104 to 1 copy.  No-template control (NTC) 
and CMV-uninfected Human Foreskin Fibroblasts (HFF) were negative controls.  CMV-
infected HFFs (HFF+ CMV) were a positive control.  10-fold serial dilution of CMV 
genomic DNA (starting with 104 copies down to 0 copies) along the x-axis.  The 
fluorescence of each droplet is displayed on the y-axis.  The pink horizontal line represents 
the threshold line dividing the positive droplets (blue dots above the threshold) from the 
negative droplets (black dots below the line); this line was based on the level of fluorescence 
present in droplets in negative control specimens.  The IE1 CMV DNA-positive and -
negative droplets show CMV DNA was detected down to 1 copy.  (b) Plot of the number of 
CMV copies measured vs the number of copies expected.  The R2 value of 0.9987 indicates 











ii. CMV Detection in Infected Cells at Low Multiplicity of Infection (MOI) 
Having shown that ddPCR could detect CMV DNA reliably in a pure DNA preparation, the 
next step was to determine if ddPCR could do the same in DNA isolated from cells infected 
with CMV.  To test this, HFFs infected at multiple MOIs including low MOIs were used.  
When MOI=1, 1 viral particle is present for each cell and using the Poisson distribution, a 
cell has more than a 69% chance of getting 1 or more copies of the virion.  Using a 
MOI=0.01 means infecting cells with 1 virion for 100 cells.  This leads to fewer cells being 
infected, replicating the conditions in PBMC where only few cells are infected with CMV.  
Using CMV− HFFs and NTC as negative controls, IE1 primers detected CMV DNA at the 
MOI of 0.01 (Figure 3.2). 
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Figure 3.2.  CMV Detection in HFFs. 
(a) CMV detection in HFFs infected with CMV at multiple MOIs.  NTC and CMV− HFF 
were negative controls.  50 ng DNA used for each well from CMV+ HFF at MOI of 1, 0.1 
and 0.01. The fluorescence of each droplet is displayed on the y-axis.  CMV DNA could be 
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iii. Comparison of ddPCR and Nested PCR 
To corroborate the accuracy of the ddPCR assay, DNA isolated from human PBMC was 
probed for IE1 using both the ddPCR and the nested PCR method.  Two CMV+ donors 
(70 and 76) and a CMV− donor (79) were tested.  The CMV serostatus of these donors had 
previously been determined by testing for CMV antibodies by ELISA.  Donors 70 and 76 
were positive, while donor 79 was negative for CMV antibodies.  For the nested PCR, in 
addition to the NTC, a no primer control (NPC) was also included as another negative 
control.  While the fluorescence threshold for most experiments was set based on the 
negative controls, in this experiment the threshold was raised to be just beneath the 
fluorescence level of the positive control.  This was done because it was unclear what the 
cluster of droplets with mid-fluorescence levels were.  One possibility was that they could be 
droplets representing a sequence variant of CMV DNA, where the IE1 primer recognizes 
the sequence but doesn’t bind as effectively as with the primary CMV strain, resulting in a 
lower level of binding and hence fluorescence.  Another possibility was that these droplets 
could be primer dimers, which occur when the primers bind to themselves; the resulting 
dsDNA can intercalate with the EvaGreen dye and fluoresce.  The lack of this cluster of 
droplets in all donors suggests that these droplets are probably not primer dimers.  However, 
to ensure that all of the droplets considered positive by the droplet reader were most likely 
to be CMV DNA, the threshold was raised to exclude the cluster of mid-fluorescence 
droplets.  This represents a conservative measurement of CMV DNA.   
 
IE1 DNA was detected in the two CMV+ donors by both ddPCR (Figure 3.3a) and nested 
PCR (Figure 3.3c).  When the CMV IE1 DNA levels detected by ddPCR were quantified 
(Figure 3.3b), the amount of CMV IE1 DNA was twice as much in donor 70 compared to 
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donor 76.  The CMV− donor 79 had above-background levels of fluorescence with the 
CMV IE1 primer, as detected by ddPCR.  However, this donor was negative for CMV IE1 
DNA by nested PCR and was CMV-seronegative by ELISA (previously performed).  
Therefore, donor 79 either was really CMV+ with very low levels of CMV DNA that could 
only be detected by ddPCR, or was a false positive by ddPCR with a high level of 
background fluorescence. 
Figure 3.3.  Detection of CMV DNA in PBMC from CMV+ and CMV− Donors. 
PBMC DNA from CMV+ donors 70 and 76 and CMV− donor 79 were (a) tested and (b) 
quantified by ddPCR, and (c) tested by nested PCR.  (a) CMV AD169 DNA was the positive 
control and NTC was the negative control.  50 ng DNA from PBMC from CMV+ donors 
70 and 76 and CMV− donor 79 was used in each well.  Each sample was run in 
quadruplicate.  Fluorescence is displayed on the y-axis.  The pink threshold line, demarcating 
the positive droplets (blue dots above the line) from the negative droplets (black dots below 
the line), was set based on the positive control to ensure all positive droplets represented 
CMV DNA.  
(b) When the amount of IE1 DNA was quantified, after subtracting the background NTC 
levels, and adjusted for the number of copies of the housekeeping gene RPP30, PBMC from 
donor 70 (4,017 IE1 copies/106 cells) and 76 (2,326 IE1 copies/106 cells) were positive for 
IE1 DNA by ddPCR.  PBMC from donor 79 had above-background levels of CMV IE1 
DNA (185 IE1 copies/106 cells).  Although it is possible that this ddPCR has detected CMV 
DNA at a very low level, the fact that this donor was negative for CMV DNA by nested 
PCR, and was confirmed to be CMV seronegative by ELISA, suggests that this ddPCR 
result is a false positive.  
(c) to confirm the results of the ddPCR, the PBMC from 2 CMV+ and the CMV− donor 
were tested by nested PCR.  CMV AD169 DNA was the positive control and NTC and no 
primer control (NPC) was used as negative controls.  125 ng DNA was used for the first 
nested PCR reaction followed by 5 µl of the PCR product for the second round of nested 
PCR.  The 55 kd band was present in the CMV+ donors 70 and 76 but absent from the 


















































iv. CMV Dilutions to Determine DNA Concentration 
To determine the optimal amount of PBMC DNA to use as the template DNA in the 
ddPCR assay, serial 2-fold dilutions of PBMC DNA were tested using the IE1 primers.  
Donor 70 PBMC DNA, that had tested positive for IE1 DNA previously by both ddPCR 
and nested PCR, was used.  Starting with 100 ng DNA, serial 2-fold dilutions down to 3 ng 
DNA were tested (Figure 3.4a).  IE1 CMV could be detected down to 6 ng DNA (Figure 
3.4b).  The negative droplets in the 100 ng DNA sample had the highest fluorescence 
compared with the negative droplets in the other samples.  High fluorescence of the negative 
droplets reduced the separation between the positive and negative droplets.  Having clear 
separation of positive and negative droplets is important to help distinguish a true positive 
droplet from a false positive.  
 
As previously discussed, the clusters of droplets beneath the threshold were not included as 
positive droplets as they may not be due to CMV DNA.  The number of droplets in these 
 59 
clusters decreased as the concentration of CMV DNA decreased.  This implies that the 
droplet fluorescence in this cluster is related to the amount of DNA detected, rather than a 
contamination or primer dimers.  It is therefore possible that CMV DNA was detected but 
has a sequence variation.  The amount of CMV IE1 DNA copies detected was regressed 
against the amount of PBMC DNA (Figure 3.4b).  The R2 value of this regression was 
0.9973, indicating that the assay is accurately detecting CMV DNA in a highly linear fashion 
with little variation.  
Figure 3.4.  Serial Dilutions of CMV DNA to Determine the Optimal Amount of 
DNA to Use in Each Well for the ddPCR Assay.  
(a) 2-fold serial dilutions made from PBMC DNA from CMV+ donor 70, from 100 ng to 3 
ng DNA.  Samples run in triplicate, with CMV genomic DNA and NTC as positive and 
negative controls, respectively.  (b) Plot of the amount of CMV IE1 DNA measured vs the 
amount of DNA in each serial dilution.  IE1 CMV DNA could be detected from 100 ng to 6 
ng DNA.  The R2 value of 0.9973 indicates high accuracy of the assay with little variation 







Each of the preceding experiments independently showed that the assay could reliably detect 
CMV DNA, and these experiments together demonstrated the validation of the ddPCR 
assay.  As discussed in detail above, these experiments showed that the assay was sufficiently 
sensitive to detect 1 copy of genomic CMV DNA and also that CMV DNA was detectable 
in CMV+ HFF infected at a low MOI.  To corroborate the detection of CMV DNA by 
ddPCR, another experiment showed that nested PCR could detect CMV DNA in donors 
where CMV DNA previously had been detected by ddPCR.  Together these results lend 
confidence to the ability of the assay to detect CMV DNA, which was subsequently tested in 
a variety of specimens. 
 
v. CMV in PBMC Compared to Monocytes 
In addition to improving the understanding of the biology of CMV and which cells are 
persistently infected with CMV, identifying cells with a higher amount of CMV DNA would 
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help validate the ddPCR assay.  It has been suggested that latent CMV virus may reside in 
monocytes.  More CMV DNA may therefore be detected by ddPCR in monocytes than in 
PBMC.  CD14+ monocytes were isolated from PBMC from HIV+ SHARE donors by 
adhering overnight in RPMI media with autologous human serum to the bottom of a plate.  
Adherence of the monocytes to the bottom of the well was confirmed by verifying the cell 
morphology under a microscope.  DNA isolated from both PBMC and monocytes from the 
same donors were tested by ddPCR for CMV IE1 DNA.  In 3 out of 4 donors the amount 
of IE1 CMV DNA detected in monocytes was less than in the PBMC DNA from the same 
donor (Figure 3.5).  These results suggest that CMV DNA was not detected in higher 
concentration in monocytes compared to PBMC.  Therefore, it is unlikely that monocytes 
are the only cells containing CMV DNA.  
 
Figure 3.5.  CMV DNA Detected in PBMC and Monocytes. 
CMV IE1 DNA levels detected in PBMC (blue) and isolated monocytes from the same 
donor (orange) assessed by ddPCR.  Monocytes were isolated from PBMC by adhering 
overnight to the bottom of a well in RPMI supplemented with autologous serum.  50 ng of 
DNA was used for each donor in duplicate.  The NTC was used as previously mentioned to 
determine the non-specific background level.  The levels of IE1 CMV DNA are expressed as 















































2. Detection and Quantification of CMV DNA Levels 
i. The Effect of CMV Serostatus on Detection of CMV DNA  
To determine whether the amount of CMV DNA in a sample correlates with CMV 
serostatus of the donor of that sample, DNA from PBMC from CMV+ and CMV− donors 
was tested by ddPCR.  CMV+ and CMV− donors were identified from a cohort of elderly 
individuals who had enrolled in a longitudinal study investigating the immune response to 
influenza vaccination.  8 CMV+ and 8 CMV− donors with multiple PBMC samples stored 
in liquid nitrogen were studied.  The average ages of the CMV+ and CMV− donors were 85 
and 85.9 years, respectively.  DNA isolated from PBMC was tested with primers for CMV 
IE1, UL54, UL55, and US28.  UL54 and UL55 primers were used because they were 
reported to be very sensitive and specific for detecting CMV DNA (123).  US28 was used 
because it encodes a latently expressed gene.  Although DNA was being tested for, rather 
than RNA or protein expression, the expected latent nature of CMV in PBMC suggested 
that targeting a CMV gene expressed during latency, such as US28, may improve the chances 
of detecting the CMV DNA. 
 
More UL55 DNA was detected in CMV+ donors compared to CMV− donors, and this 
difference was significant (p=0.04 by a Mann-Whitney U test; Figure 3.6a).  IE1 and UL54 
CMV DNA were also more abundant in the CMV+ donors, but not significantly so (p> 
0.05), although the difference in levels of UL54 DNA was of borderline significance 
(p=0.07) (Figure 3.6b). 
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Figure 3.6.  CMV DNA Detected in CMV+ and CMV− Donors. 
CMV DNA levels in CMV+ donors compared to CMV− donors.  (a)  PBMC DNA from 8 
CMV+ donors (blue) were compared with PBMC DNA from 8 CMV− donors (orange).  
Serostatus of all donors had previously been confirmed in Dr. Leng’s geriatric study by an 
antibody test and by nested PCR.  DNA was isolated from PBMC from all donors and IE1, 
US28, UL54, and UL55 DNA was quantified by ddPCR.  Bars indicate the medians, and 
error bars indicate the interquartile range.  Significantly more UL55 CMV DNA was 
detected in the CMV+ donors than in the CMV− donors (shown by * which denotes 
p=<0.05).  IE1 and UL54 DNA were also higher in the CMV+ donors, but not significantly 
so.  (b) The median for each CMV gene in each group is shown, along with the p-value for 








































CMV gene tested 
CMV- donor CMV+ donor
* 
* p= <0.05 
  





IE1 92.69 150.40 0.29 
US28 450.56 480.67 0.87 
UL54 1267.79 1793.31 0.07 
UL55 101.84 265.86 0.04 
 64 
ii. Background Fluorescence Levels of CMV Primers and Probes in CMV− 
Donors 
To determine if the positive droplets seen in CMV− donors from previous experiments truly 
represented CMV DNA or were false positives, specimens from known CMV− donors were 
tested for CMV DNA by ddPCR.  These included mouse tail DNA, DNA from CMV− 
THP-1 cells from different days in culture (day 1 and day 9), and PBMC from a CMV− 
leukopak.  Multiple primers were tested: IE1, UL54, and UL55, and a primer/probe set that 
detected CMV gB DNA.  The gB probe had been used in previous studies and was thought 
to be more specific than the primers (119).  As discussed in the Methods section, the probe 
and primers use different mechanisms of binding to the target gene and generating 
fluorescence in the ddPCR droplet. 
 
Specimens from the CMV− donors were tested with the primers in duplicate with 4 NTC 
samples, and with the gB probe in triplicate with 9 NTC wells.  The threshold for positive 
fluorescent droplets was set above droplets in the NTC or beneath the CMV AD169 
genomic DNA in the positive control.  Setting the threshold at this level, the NTCs of the 
IE1 (Figure 3.7a), UL54 (Figure 3.7b), and UL55 (Figure 3.7c) primers had totals of 1, 9, and 
4 positive droplets, respectively (out of more than 15,000 in most cases) in the 4 NTC 
replicate wells.  The gB probe (Figure 3.7d) had no positive droplets in any of the 9 replicate 
wells.  
 
UL54, UL55, or the gB probe showed no positive fluorescent signal in the THP-1 D1 and 
the leukopak DNA (Figure 3.7e).  In contrast, mouse tail DNA and the THP-1 D9 cells 
were positive for all primers at very low levels.  The background (non-specific) level of the 
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IE1 primers was very low in each CMV− sample tested, with a few positive droplets present.  
The UL55 primers showed no nonspecific background as they were undetectable in the 
THP D1 and the leukopak, and only a very low level of nonspecific positivity was present in 
the THP D9 sample.  The THP-1 D9 also showed a small positive fluorescent signal for the 
gB probe which was absent in all the other samples tested.  Results were expressed as the 
number of copies/106 cells for all specimens, except for mouse tail DNA which does not 
contain the RPP30 gene used to normalize to the number of cells in human specimens. 
 
These data demonstrated that, to accurately quantify the amount of rare CMV DNA, it is 
necessary to take into account false-positive or background levels of fluorescence, especially 
when using the CMV primers.  The gB probe showed better specificity than the primers and 
no background in the majority of donors tested.  Therefore, for subsequent experiments in 
this project, multiple negative control samples in duplicate or triplicate were used in addition 
to the NTC, especially when using the primers.  An average of the nonspecific background 
levels measured in the CMV− samples was calculated for each primer.  This average 
background level in known CMV− samples was subtracted from the amount of CMV DNA 
recorded in the studied samples. 
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Figure 3.7.  Non-Specific Fluorescence of Droplets in CMV− donors. 
 CMV− donors: Mouse tail, CMV− THP-1 cell DNA from day 1 of culture (THP1 D1) and 
day 9 of culture (THP1 D9), and CMV− leukopak DNA were tested for CMV DNA using 
the (a) IE1, (b) UL54, and (c) UL55 primers.  CMV AD169 genomic DNA was the positive 
control and NTC was the negative control.  Samples were run in duplicate with 4 NTC wells.  
The threshold for positivity of droplet fluorescence was set based on the fluorescence of 
droplets in the NTC.  A few positive droplets were present in all CMV− specimens.  (d) 
Testing the specimens from the CMV− donors with the gB probe in triplicate with 9 NTC 
wells.  No positive droplets were present in specimens from CMV−donors, except THP1-
D9.  (e) Depiction of the quantified levels of positive signal above NTC background.  The 
lack of RPP30 in mouse tail prevented the calculation of the amount of DNA/106 cells.  The 
y-axis represents the amount of background positive signal measured/well.  Positive 
fluorescent signal was absent for the UL54 and UL55 primers in DNA from THP1-D1 and 
the leukopak PBMC.  Mouse tail showed positive fluorescent signal for IE1, UL54, and 
UL55 primers.  The IE1 primer showed positive fluorescent signal in all the samples tested.  
The gB probe showed no positive fluorescent signal in except in the THP-1 D9 cells, 

























iii. CMV DNA Detection in Semen From HIV+ Men Not Receiving HAART 
With CMV DNA rare and hard to detect in people latently infected with CMV, and with the 
presence of very low-level fluorescence using the CMV primers in the ddPCR assay, 
validation of the assay as used above required that a human specimen with unequivocal 
CMV DNA content be found, to serve as a true positive control.  To this end, it was decided 
to test semen from HIV+ individuals not receiving HAART for CMV DNA.  We reasoned 
that because HAART suppresses HIV viremia to undetectable levels, people with HIV 
infection not receiving HAART have higher HIV viremia and more impairment of cellular 
immunity than people receiving HAART.  Therefore, people not receiving HAART would 
be less likely to be able to control CMV replication than people receiving HAART, and 
might have more CMV DNA in their semen.  To confirm that the ddPCR assay could detect 
CMV in semen, semen from 20 HIV+ men not receiving HAART was studied using the gB 
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gB DNA was detected in 9 of the 20 semen samples (Figure 3.8a).  In the 9 samples where 
gB DNA was detected, the median was 1.4x104 copies/106 cells.  The ability to clearly detect 
CMV DNA in a biological sample and not just in the pure CMV genomic DNA or the 
CMV-infected HFF, was a big step forward for the project.  It showed that the assay worked 
and CMV DNA could be detected.  These semen samples with detectable CMV DNA also 
served as a valuable positive control for future experiments, alongside the CMV AD169 
genomic DNA. 
 
To test whether the primers and the probe were equally sensitive and specific, results 
obtained using the primers (IE1, UL54, and UL55) were compared to those obtained using 
the gB probe (Figure 3.8b) in 13 donors.  These 13 semen samples selected included 5 with 
the highest levels of gB DNA detected, and 8 that had undetectable gB CMV DNA.  This 
was to test whether the primers detected CMV DNA in samples that were positive for gB 
DNA, supporting the data obtained using the probe.  It also tested whether the primers 
could detect CMV DNA in samples that were negative for gB DNA, which would either 
corroborate the gB probe data or show any differences between the primers and the probe. 
 
CMV DNA was detected in all 13 semen samples.  IE1 DNA was detected in 11 samples 
(median= 0.5x104 copies/106 cells), and UL54 (median= 0.8x104 copies/106 cells), and UL55 
(median= 1.7x104 copies/106 cells) were detected in 10 donors.  The median amount of gB 
DNA detected in the 5 donors was 9.8x104 copies/106 cells).  All semen samples but 2 had 
multiple target genes detected, and the two remaining samples had only UL55 DNA 
detected in both cases.  The levels of CMV DNA detected by the UL55 primer and the gB 
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probe were strongly correlated (R2 = 0.99) (Figure 3.8c).  This strong correlation supports 
the accuracy of the assay to detect CMV DNA, because the UL55 primer and the gB probe 
target DNA sequences in the same CMV gene.  However, the probe detected CMV DNA in 
only half as many donors as the primer, 5 and 10 out of 13, respectively.  The probe is more 
specific than the primer as shown by the much lower background levels from the probe.  
However, the primer may be more sensitive than the probe and detect CMV DNA at low 
levels.  It is also possible that lower specificity of the primer means that some of the UL55 
DNA detected may be false positive.  This may occur at the lower level of detection, but 
when UL55 and gB are both detected, the levels of CMV DNA measured are very similar.    
 
 
Figure 3.8. CMV DNA Detection in Semen from HIV-Infected Donors Not 
Receiving HAART. 
(a) CMV DNA detection by gB probe in semen from 20 donors.  x-axis is each donor (1-20), 
the y-axis is CMV DNA (copies/106 cells).  gB was detected in 9 out of 20 donors.  (b) CMV 
DNA detected by primers: IE1 (blue), UL54 (orange), UL55 (grey), and gB probe (yellow).  
CMV DNA was detected in all 13 semen samples.  (c) Correlation between the amount of 
CMV DNA detected by the UL55 primer (x- axis) vs the amount detected by the gB probe 
(copies/106 cells) (y-axis).  In specimens in which CMV DNA was detected by both the 



































Table 3.1.  CMV DNA Detected by CMV Primers and Probe in Each Donor.  
 Median amount of CMV DNA detected  
(copies/106 cells) 
Donor IE1 UL54 UL55 gB 
5 0 0 1655 0 
6 2218 205 0 0 
7 35 1429 1429 1404 
8 133 2000 1000 0 
9 4251 0 10627 9767 
11 0 0 816 0 
12 65446 47863 68921 60837 
13 501 1894 6295 0 
14 917 344 0 0 
15 88 1316 0 0 
16 3313 798 2577 870 
19 70740 91945 85420 76723 































iv. CMV DNA Detection in PBMC from HIV+ Men Not Receiving HAART 
Having detected CMV DNA in semen from a number of HIV+ individuals not receiving 
HAART, we asked whether PBMC from HIV+ individuals not receiving HAART also had 
detectable CMV DNA.  As previously mentioned, these individuals not receiving HAART 
had higher HIV viremia and more impaired cellular immunity.  This makes them less likely 
to control CMV replication and therefore more likely to have CMV in their PBMC.  
Therefore, cryopreserved PBMC from 20 HIV-infected SHARE participants originally 
obtained when they were not receiving HAART were tested for CMV DNA by ddPCR 
using the gB probe and the IE1, UL54, and UL55 primers.  A semen sample from an HIV-
infected donor not receiving HAART, which had previously been shown to be positive for 
all CMV genes tested by the primers and the probe, was also used as a positive control 
alongside the CMV AD169 genomic DNA. 
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Using the gB probe, CMV DNA was detected in PBMC from 16 out of 20 donors (Figure 
3.9a).  The median amount of gB CMV DNA detected was 44.9 copies/106 cells (Figure 
3.9b).  However, some donors showed much higher levels of CMV DNA in their PBMC, 
with the median of the 4 highest responders being 2.3x104 copies/106 cells.  The use of 
HIV+ donors not receiving HAART enabled the detection of CMV DNA and provided 
samples that could be used in future experiments as a biological positive control, in addition 
to AD169 genomic DNA.  The findings showed that the assay could detect CMV DNA in 
PBMC.  This enabled the project to continue and investigate the relationship between CMV 
DNA and the T cell response to CMV. 
 
The 4 donors with the highest levels of gB DNA detected were subsequently tested with the 
CMV primers IE1, UL54, and UL55 to determine if the probes and primers gave similar 
results (Figure 3.9c).  UL54 and UL55 DNA were detected at similar levels compared to the 
gB probe, with median values: 3.2x104 copies/106 cells and 3.4x104 copies/106 cells, 
respectively, but levels of IE1 DNA were slightly lower at an average of 0.7x104 copies/106 
cells.   
 
The gB probe identified clusters of droplets with differing fluorescence levels, all above the 
background levels, but less than the positive control AD169 DNA.  These could be 
sequence variations in different strains than the gB probe can identify.  The lack of 
background from the probe allows the identification of these clusters and the confidence 
that these droplets represent CMV DNA. 
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The amounts of CMV DNA detected using the different CMV primers and the gB probe 
were also very similar.  Comparing the amount of CMV detected using the UL55 primers 
with the quantity of CMV detected using the gB probe (Figure 3.9d) for each donor also 
showed a very strong correlation (R2 = 0.92).  This was expected, because the gB probe and 
the UL55 primers target the same UL55 gene. 
 
The results of these experiments showed that the ddPCR assay could quantify CMV DNA in 
PBMC and semen from donors.  CMV DNA was detected in greater amounts in CMV+ 
donors compared to CMV− donors.  In non-suppressed HIV-infected donors who were not 
receiving HAART, CMV DNA could be detected and quantified in both PBMC and semen.  
As discussed previously, the amounts of UL55 DNA and gB DNA detected in both PBMC 
and semen showed a strong correlation when both were detected in the same sample.  In 
addition to the donors for whom gB DNA was detected, the UL55 primer detected CMV 
DNA in some semen samples from donors that did not yield detectable gB DNA.  The latter 
donors had lower amounts of CMV DNA than the donors who had both UL55 and gB 
DNA (Table 3.1).  This may be due to differences in the sensitivity of the UL55 primer 
compared to the probe.  Although the gB probe has a high specificity, shown by the lack of 
non-specific background fluorescence levels in CMV− samples, it is possibly less sensitive 
than the UL55 primers and may miss some CMV DNA only detected at a low level.  The 
lower specificity of the UL55 primers, shown by the higher background levels in CMV− 
samples than the gB probe, raised the possibility that donors with only UL55 DNA detected 
at a low level may be false positives.  However, multiple DNA targets were detected in most 
donors and similar amounts of CMV DNA were detected by each primer and the probe.  
Although the background levels were higher with the primers, a positive signal above 
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background could still be measured in the PBMC and semen from these HIV-infected 
donors not receiving HAART.  
 
The conclusion of these experiments was that ddPCR could quantify CMV DNA in PBMC.  
Therefore, the next step in this project was to determine if the detection of CMV DNA in 
PBMC was correlated with the T cell responses to CMV in the same donors. 
 
 
Figure 3.9.  CMV DNA Detection in PBMC from 20 HIV-Infected Donors Not 
Receiving HAART. 
(a) 50 ng DNA from PBMC from 20 HIV+ donors not receiving HAART was tested by 
ddPCR using the gB probe for CMV DNA in duplicate.  Each HIV+ donor not receiving 
HAART is along the x-axis.  CMV AD169 and 50 ng DNA from semen from a non-
suppressed HIV-infected donor were used as the positive controls.  4 NTC wells were the 
negative controls.  The threshold for the gB probe was set above the negligible NTC 
background level and above the cluster of droplets with low fluorescence, as it was unclear 
whether they represented true positives for CMV DNA fluorescence.  Other clusters of 
droplets with different fluorescence were considered positive and quantified as detectable 
CMV DNA.  (b) The amount of gB DNA copies/106 cells.  The average amount of gB 
DNA detected (7674 copies/106 cells) from the 20 donors with error bars showing the 
standard deviation.  (c) Graph showing the CMV levels in PBMC from the 4 donors with 
the highest amount of gB detected.  These PBMC were tested with IE1 (blue), UL54 
(orange), and UL55 (grey) primers.  The amount of gB (yellow) DNA detected is also 
shown.  The average amount of CMV DNA detected by each primer and the probe is 
shown, with error bars indicating the standard deviation.  Similar amounts of CMV DNA 
were detected with the primers and with the probe.  (d) Graph correlating the CMV DNA 
levels measured with the UL55 primer and with the gB probe.  The R2 value of 0.9225 shows 
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 The Relationship Between CMV DNA Levels and T C.
Cell Responses to CMV  
Having established and validated an assay to quantify CMV DNA in PBMC from various 
types of human donors, including virologically suppressed HIV+ donors receiving HAART, 
the next aims were to determine: (1) whether the amount and type of CMV DNA in PBMC 
were associated with the T cell response to CMV; and (2) if so, whether these associations 
were correlated with HIV status or frailty status. 
 
To address these aims, CMV DNA was measured in PBMC from donors whose T cell 
responses to CMV had previously been measured (8).  In the previous study, PBMC from 42 
SHARE participants were stimulated with overlapping peptides that covered 19 CMV ORFs, 
and the proportion of CD4+ and CD8+ T cells producing IFNγ, TNF, and IL-2 in response 
to this stimulation was measured.  This broad range of peptides was used because of the 
wide range of CMV antigens that can stimulate CMV-specific T cells (48).  These subjects 
also presented a diversity of HIV status (half +, half −) and frailty status (half +, half −), 
making them an ideal group for the present study. 
 
The amount of CMV DNA in PBMC from these donors was quantified.  The CMV primers 
(IE1, UL54, and UL55) and the gB probe quantified differences in the amount of each CMV 
gene detected.  The T cell responses to CMV were compared between those donors with 
detectable CMV DNA and those without CMV DNA.  A Mann-Whitney U test was used to 




1. Presence of CMV DNA in PBMC from 36 SHARE Participants 
Analyzed  
Of the 42 donors in the previous study, 6 did not have cryopreserved PBMC available for 
testing.  Therefore, 36 donors were tested: 19 were HIV+ and 17 were HIV−; 18 were 
frailty+ and 18 were frailty−.  The 6 donors that were not tested included: 3 HIV+ and 3 
HIV− and 3 frailty+ and 3 frailty−.  In the group as a whole (Table 3.2), CMV DNA was 
detected in 30 out of 36 donors (83.3%): DNA for IE1 was detected in 10 donors (27.8%), 




Table 3.2. Characteristics and Results for 36 Donors Tested for CMV DNA. 
HIV− (n=17) and HIV+ (n=19); frailty− (n=18) and frailty+ (n=18); HIV-frailty 
















Presence of gB 
DNA 
35 64 - - - + + + 
39 66 - - - + + + 
41 65 - - + + + - 
44 49 - - - + + + 
50 63 - - - + - + 
52 70 - - + + + + 
54 62 - - - - - - 
68 70 - - - - - - 
69 73 - - + + + 
 
32 62 - + - + + - 
33 54 - + + + + - 
36 56 - + + + + + 
40 65 - + - + - - 
43 64 - + + + + + 
53 66 - + - + - - 
61 69 - + - - - - 
63 67 - + - - - + 
26 55 + - + + + + 
30 63 + - - + - - 
37 54 + - - + + - 
46 64 + - - + + - 
48 65 + - - + + - 
55 51 + - + + - - 
58 61 + - - + - - 
66 61 + - + - + + 
70 61 + - - + - - 
29 52 + + - + + + 
31 59 + + - + - - 
38 69 + + - + + + 
42 57 + + - - + - 
47 55 + + - + + + 
49 58 + + - + + + 
56 68 + + - + - - 
60 52 + + - - - - 
64 66 + + + + - + 
65 64 + + - - - - 
HIV seropositive= +, HIV seronegative= −; frailty+ = positive for Fried frailty phenotype, 
frailty− = negative for Fried frailty Phenotype; IE1/UL54/UL55/gB DNA + = CMV DNA 




2. The Relationship Between Concentrations of CMV DNA, HIV Status, 
and Frailty Status  
When analyzed by HIV status (Figure 3.10a), CMV DNA was detected by the UL54 and 
UL55 primers and by the gB probe (Table 3.3).  However, the differences between the 
amount of CMV DNA detected in the HIV+ and the HIV− groups were not significant for 
any of these genes.  The average amount of gB DNA detected was 5 times higher in HIV− 
donors compared to HIV+ donors but this difference was not significant.  Similarly, 
concentrations of UL54 and UL55 DNA were higher in HIV+ compared to HIV− donors, 
but not significantly so.  Median IE1 DNA concentrations were not above background in 
either HIV− or HIV+ donors.   
  
CMV DNA concentrations did not differ by frailty status (Figure 3.10b) for any of the CMV 
genes studied (Table 3.4).  Levels of DNA detected were generally higher in the non-frail 
compared to the frail donors.  The average amount of UL55 DNA was 3 times higher in 
frailty− donors compared to frailty+ donors, and with a p-value of 0.13 the difference 
between the groups was close to being significant.  Similarly, UL54 DNA concentration was 
higher in frailty− donors compared to frailty+ donors but was not a significant difference.  
The median concentrations of IE1 and gB DNA were not above background in either the 
frailty− or the frailty+ donors.  However, high levels of CMV DNA, especially gB DNA, 
were detected especially in frailty− donors. 
 
CMV DNA concentrations for each gene tested did not differ between each HIV-frailty 
subgroup (Figure 3.11).  Although the median concentration of IE1 DNA (Figure 3.11a) was 
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not above background in any subgroup (Table 3.5), IE1 DNA was detected in donors, 
especially donors in the HIV+ frailty− and the HIV− frailty+ subgroups.  The difference in 
IE1 DNA concentration between the HIV+ frailty− and the HIV+ frailty+ subgroups was 
almost significant (Table 3.6).  
 
UL54 DNA was detected in each HIV-frailty subgroup (Figure 3.11b), although none of the 
differences were significant (Table 3.8).  Nevertheless, higher concentrations of UL54 DNA 
were detected in frailty− donors of both HIV+ and HIV− serostatus (Table 3.7).  
 
In addition, the amount of UL55 DNA (Figure 3.11c) and gB DNA (Figure 3.11d) showed 
no significant differences between any of the subgroups (Tables 10 and 12).  For UL55 
DNA, the median amount was 3-6 times higher in the HIV− frailty− subgroup compared to 
the other subgroups (Table 3.9).  While the median amount of gB DNA was not detectable 
in HIV− frailty+ and HIV+ frailty− donors (Table 3.11), the difference between the amount 




Figure 3.10.  CMV DNA Levels in PBMC from Donors Stratified by HIV and Frailty 
Status 
Amount of CMV DNA for each primer (IE1, UL54, and UL55) and probe (gB) was 
compared by (a) HIV serostatus and by (b) frailty status.  The black lines represent the 
median for each group.  There were no significant differences between either the HIV+ and 




Table 3.3.  Median Amount of CMV DNA Detected for Each CMV Gene by HIV 
Serostatus   
The p-value determines if there was a significant difference between the HIV+ (n=19) and 
the HIV− (n=17) group for each CMV gene. 
CMV gene HIV serostatus 




−  ND 0 – 105.1 
0.75 
+ ND 0 – 0 
UL54 
−  482.1 0 – 756.0 
0.75 
+ 439.0 83.9 – 661.0 
UL55 
−  46.9 0 – 156.6 
0.9 
+ 42.6 0 – 143.4 
gB 
−  46.2 0 – 108.7 
0.3 
+ ND 0 – 61.6 








HIV- HIV+ HIV- HIV+ HIV- HIV+ HIV- HIV+


























Table 3.4.  Median Amount of CMV DNA Detected for Each CMV Gene by Frailty 
Status 
The p-value determines if there was a significant difference between the frailty+ (n=18) and 
the frailty−(n=18) group for each CMV gene. 
CMV gene Frailty status 




− ND 0 – 43.8 
0.5 
+ ND 0 – 0 
UL54 
− 541.7 118.9 – 743.3 
0.5 
+ 418 52.8 – 567.2 
UL55 
− 60 0 – 164.2 
0.1 
+ 21.7 0 – 67.2 
gB 
− ND 0 – 74.5 
0.9 
+ ND 0 – 70.2 
Frailty− = negative for Fried frailty Phenotype; frailty+ = positive for Fried frailty 









Frailty- Frailty+ Frailty- Frailty+ Frailty- Frailty+ Frailty- Frailty+




















CMV DNA detected in frailty− and frailty+ for each CMV gene 
 87 
Figure 3.11.  CMV DNA Levels in PBMC from Donors Stratified by HIV-Frailty 
Subgroup for Each CMV Gene Tested 
(a) IE1, (b) UL54, (c) UL55, and (d) gB.  CMV DNA was detected in each HIV-frailty 




Table 3.5.  Median Concentrations of IE1 DNA Detected in Each HIV-Frailty 
Subgroup 
HIV serostatus Frailty status 




− ND 0 – 45.5 
+ ND 0 – 109.9 
HIV+ 
− ND 0 – 38.9 
+ ND 0 – 0 
Frailty− = negative for Fried frailty phenotype; frailty+ = positive for Fried frailty 





































Table 3.6.  P- values for Comparisons Between HIV-Frailty Subgroups for IE1 DNA 
Detected 
 HIV− frailty+ HIV+ frailty− HIV+ frailty+ 
HIV− frailty− 0.5 0.7 0.8 
HIV− frailty+  0.5 0.5 




Table 3.7.  Median Concentrations of UL54 DNA Detected in Each HIV-Frailty 
Subgroup 
HIV serostatus Frailty status 




− 599 423.4 – 834.2 
+ 437 158.4 – 712.5 
HIV+ 
− 532.6 100.6 – 705.2 
+ 418 60.8 – 540.8 
Frailty− = negative for Fried frailty phenotype; frailty+ = positive for Fried frailty 


































Table 3.8.  P- values for Comparisons Between HIV-Frailty Subgroups for UL54 
DNA Detected 
 HIV− frailty+ HIV+ frailty− HIV+ frailty+ 
HIV− frailty− 0.79 0.81 0.56 
HIV− frailty+  0.89 0.97 




Table 3.9.  Median Concentrations of UL55 DNA Detected in Each HIV-Frailty 
Subgroup 
HIV serostatus Frailty status 




− 134.1 0 – 166.7 
+ 22.6 0 – 53.5 
HIV+ 
− 42.6 0 – 148.4 
+ 21.7 0 – 116.1 
Frailty− = negative for Fried frailty phenotype; frailty+ = positive for Fried frailty 







































Table 3.10.  P-values for Comparisons Between HIV-Frailty Subgroups for UL55 
DNA Detected 
 HIV− frailty+ HIV+ frailty− HIV+ frailty+ 
HIV− frailty− 0.3 0.9 0.5 
HIV− frailty+  0.4 0.6 




Table 3.11.  Median gB DNA Detected in Each HIV-Frailty Subgroup 
HIV serostatus Frailty status 




− 60.4 0 – 184.9 
+ ND 0 – 93.1 
HIV+ 
− ND 0 – 0  
+ 28.71 0 – 69.9 
Frailty− = negative for Fried frailty phenotype; frailty+ = positive for Fried frailty 




































Table 3.12.  P-values for Comparisons Between HIV-Frailty Subgroups for gB DNA 
Detected 
 HIV− frailty+ HIV+ frailty− HIV+ frailty+ 
HIV− frailty− 0.4 0.1 0.5 
HIV− frailty+  0.5 1.00 
HIV+ frailty−   0.3 
 
3. The Relationship Between CMV DNA Levels and T Cell Responses to 
CMV Peptides 
Having detected the amount of each CMV DNA, the donors were dichotomized into two 
groups: the top 25% of donors were considered those in whom the DNA was detected and 
the lower 75% of donors those in whom it was not.  The number of T cells responding to a 
CMV peptide was compared between these two groups.  This analysis was further stratified 
by the type of T cell responding to the CMV peptide (CD4 or CD8), by the cytokine 
produced by the T cell (IFNγ, TNF, or IL-2), and finally, by the CMV peptide that 
stimulated the T cell response.  A Mann-Whitney U test was used to determine significance 
of differences in the T cell responses between those donors with and without detectable 
CMV DNA. 
 
Some donors with detectable CMV DNA had T cell responses to CMV peptides.  These 
responses varied depending on which CMV DNA was detected, which cells were responding 
to the CMV peptide, which cytokine was produced, and which peptide was stimulating the 
response.  In addition to the T cell responses seen when CMV DNA was detected, some 
donors with undetectable CMV DNA had T cell responses to CMV peptide stimulation.   
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This section will first describe the T cell response in donors with detectable DNA, followed 
by the response seen in donors without detectable DNA.  Next, it will present the effect that 
the presence of detectable CMV DNA had on the T cell response to CMV in HIV infection 
and in frailty.   
 
i. T Cell Responses to CMV Peptide Stimulation in Donors When CMV DNA 
Was Detected 
Donors with detectable CMV DNA had higher proportion of CMV-responsive T cells than 
donors with undetectable CMV DNA.  This difference between the donor groups was 
significant depending on which cell responded by producing which cytokine.  For example, 
donors with detectable UL54 DNA had a higher frequency of CD4 and CD8 T cells 
producing TNF in response to CMV stimulation than donors with undetectable UL54 DNA 
(Table 3.14).  Another example was donors with detectable UL55 DNA, who had a greater 
number of CD4 cells that produced IL-2 in response to CMV peptide stimulation compared 
to donors with undetectable UL55 DNA (Table 3.15).  In addition to the significant 
difference in the number of CD4 cells producing IL-2 in response to a variety of CMV 
peptides in donors with UL55 DNA detected, the total number of CD4 cells producing IL-2 




ii. T Cell Responses to CMV Peptide Stimulation in Donors When No CMV 
DNA Was Detected 
Some donors had higher CMV-specific T cell responses when no CMV DNA was detected, 
compared to donors with detectable CMV DNA.  For example, donors with undetectable 
IE1 DNA had a higher number of CMV-specific T cells producing a variety of cytokines, 
compared to donors with detectable IE1 DNA (Table 3.13).  The number of CD4 and CD8 
cells producing IFNγ, IL-2, and TNF were all higher in donors with undetectable IE1 DNA 
compared to donors with detectable IE1 DNA.  Donors with other undetectable CMV 
DNAs, such as UL55 and UL54, had T cell responses to CMV that differed from the 
responses previously mentioned in donors with detectable amounts of these DNA.  CD4 T 
cells showed higher IFNγ responses while CD8 T cells showed higher IFNγ, IL-2, and TNF 
responses in donors without UL55 DNA (Table 3.15).  Other than showing the complexity 
of the T cell responses to CMV, these results show how detectable, or undetectable CMV 
DNA can affect these responses.  
 
iii. The Effect of the Detection of CMV DNA on the T Cell Response to 
Stimulation Using a Related Peptide 
If the CMV DNA is having an effect on the T cell response, it would be important to 
determine the importance of the specific CMV peptide used to stimulate the T cell response.  
Therefore, we studied whether the T cell response was different when it was stimulated by a 
CMV peptide that was closely related to the CMV DNA detected (Table 3.20).  The number 
of CD4 T cells that produced TNF in response to stimulation by UL55 peptide was 
significantly different between HIV− frailty+ donors with detectable gB DNA or HIV+ 
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frailty− donors with detectable UL55 DNA, compared to donors with either DNA 
undetectable (Table 3.19).  
 
In contrast, in one subgroup of donors (HIV+ frailty+), the number of CD8 T cells that 
produced either IFNγ (Table 3.17) or TNF (Table 3.19) in response to stimulation by the 
UL123 peptide was significantly different between donors with undetectable IE1 DNA, 
compared to those donors with detectable IE1 DNA (Table 3.20).  Together these results 
suggest a link between the peptide stimulating the T cell response, the T cell response to the 
stimulation, and detectable or undetectable CMV DNA. 
 
iv. The Effect of Detectable CMV DNA on T Cell Responses to CMV in HIV 
and frailty 
Having determined that detected CMV DNA may have an effect on T cell responses to 
CMV, the next aim of the project was to see if these effects were associated with HIV status 
and/or frailty status.  Overall, the detection of CMV DNA was indeed associated with the T 
cell responses in donors, and this effect seemed to be unrelated to either HIV serostatus or 
frailty status on their own.  However, when the results were further stratified into subgroups 
by HIV and frailty status, significant differences in T cell responses could be seen between 
donors with detectable DNA and those with undetectable DNA. 
 
HIV+ frailty− donors had a higher frequency of CD4-responsive cells producing IL-2 when 
gB DNA was detected and also when UL55 DNA was detected, compared to donors with 
either DNA undetectable (Table 3.18).  The fact that the gB probe and the UL55 primer 
each independently detected CMV DNA in donors, and that significant differences were 
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seen in the T cell response between these donors who had detectable CMV DNA and those 
donors without detectable CMV DNA, strengthens the results. 
 
In HIV− frailty+ donors, there was a higher frequency of CD8 CMV-responsive cells 
producing IFNγ when gB DNA was detected and also when UL54 DNA was detected, 
compared to donors with either DNA undetectable (Table 3.17).  This demonstrated a 
relationship between the detection of CMV DNA and the T cell responses in frail donors 
who were HIV−.  
 
Significant differences in the same T cell response were seen in donors who were positive 
for multiple CMV DNA compared to those with undetectable CMV DNA, suggesting that 
the detection of CMV DNA may be linked to specific T cell responses to CMV. 
 
v. Significant Differences in the T Cell Responses to CMV Between the HIV-
Frailty Subgroups, Regardless of the Detection of CMV DNA  
To test if there were significant differences in the T cell responses to CMV between the 
HIV-frailty subgroups, we compared the T cell responses to peptide stimulation in each 
HIV-frailty subgroup.  Significant differences were seen between the HIV-frailty subgroups.  
The majority of significant differences in T cell responses to CMV stimulation were present 
in donors with undetectable CMV DNA.  For example, the proportion of CD4 CMV-
responsive T cells and the CD8 CMV-responsive T cells producing IFNγ showed significant 
differences between the HIV-frailty subgroups (Table 3.21).  
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A potential link between gB DNA and CD4 cells producing IL-2 (mentioned earlier) was 
supported by finding of significant differences in the frequency of these cells between the 
HIV-frailty subgroups when gB DNA was not detected in donors (Table 3.22). 
 
Also, there were significant differences between the T cell responses of the HIV-frailty 
subgroups to specific CMV peptides.  For example, stimulation of CD4 cells with the CMV 
peptide UL82 resulted in a significant difference in the T cell IFNγ response in the HIV-
frailty subgroups when any of the CMV DNAs (i.e., IE1, UL54, UL55, and gB) were not 
detected (Table 3.21).  This analysis helps identify which peptides have effects on the T cell 
responses in each HIV-frailty subgroup.   
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Table 3.13.  Significant Differences in the Frequency of T Cell Responses to CMV 
Peptides Between Donors with Detectable IE1 DNA and Those with Undetectable 














CD4 IFNγ UL32b 0.01 0 0.06 
UL99 0.03 0.01 0.02 
UL122 0.03 0 0.004 
 IL-2 UL36 0.06 0.01 0.007 
UL83 0.1 0.02 0.007 
UL99 0.03 0 0.01 
UL122 0.03 0.01 0.02 
TNF UL32b 0.03 0 0.005 
UL122 0.03 0 0.03 
CD8 IFNγ 
 
UL123 1.25 0.25 0.01 
UL151 0.03 0 0.05 
IL-2 UL36 0.05 0 0.01 
UL94 0.01 0 0.03 
UL123 0.08 0.01 0.005 
UL153 0.01 0 0.04 
US3 0.01 0 0.03 
TNF 
 
UL123 1.02 0.15 0.007 
UL151 0.03 0 0.05 
Data are the median percentages of CD4 or CD8 T cell responses to CMV stimulation 




Table 3.14.  Significant Differences in the Frequency of T Cell Responses to CMV 
Peptides Between Donors with Detectable UL54 DNA and Those with Undetectable 














CD4 IFNγ UL32a 0.11 0 0.008 
UL48-b 0.01 0 0.05 
UL55-a 0.07 0.01 0.02 
UL99 0.03 0 0.02 
UL123 0.03 0 0.009 
US24 0.01 0 0.02 
IL-2 UL86-b 0 0.09 0.06 
TNF UL28 0.01 0.06 0.04 
UL48 pool 0.02 0.05 0.03 
UL86-b 0.01 0.2 0.02 
CD8 IFNγ UL48-b 0.02 0 0.04 
TNF UL48 pool 0.01 0.14 0.005 
UL48d 0 0.08 0.001 
UL55a 0.01 0.1 0.01 
UL122 0.04 0.11 0.06 
Data are the median percentages of CD4 or CD8 T cell responses to CMV stimulation 





Table 3.15.  Significant Differences in the Frequency of T Cell Responses to CMV 
Peptides Between Donors with Detectable UL55 DNA and Those with Undetectable 
















CD4 IFNγ UL55-b 0.06 0.53 0.007 
UL82 0.03 0 0.02 
UL86-a 0.06 0 0.009 
UL103 0.02 0 0.05 
IL-2 UL48-a 0 0.09 0.02 
UL48-c 0 0.05 0.03 
UL55-b 0.03 0.31 0.02 
UL94 0 0.07 0.02 
US24 0 0.01 0.06 
Total CD4 IL-2  0.94 4.16 0.046 
CD8 IFNγ UL32-a 0.03 0 0.008 
UL48-a 0.01 0 0.04 
UL48-c 0.01 0 0.04 
UL82 0.03 0 0.06 
UL86-b 0.03 0 0.03 
IL-2 UL28 0.01 0 0.03 
UL86-a 0.01 0 0.03 
UL86-b 0.01 0 0.02 
UL99 0.01 0 0.04 
UL151 0.02 0 0.05 
US29 0.02 0 0.06 
US32 0.09 0.01 0.05 




  4.6 1.8 0.06 
Data are the median percentages of CD4 or CD8 T cell responses to CMV stimulation 
Bold = the higher T cell response between donors with detectable or with undetectable 
CMV DNA. 




Table 3.16.  Significant Differences in the Frequency of T Cell Responses to CMV 
Peptides Between Donors with Detectable gB DNA and Those with Undetectable 


















UL103 0 0 0.035 
UL153 0 0.5 0.021 
















2.2 0.5 0.007 
Data are the median percentages of CD4 or CD8 T cell responses to CMV stimulation 






Table 3.17.  Significant Differences in The Frequency of T Cells Producing IFNγ in 
Response to CMV Peptides Between Donors with Detectable CMV DNA and Those 


















HIV−  Frail− CD4 UL54 UL123 0 0 0.043 
UL48 pool 0 0.2 0.036 
US24 0 0 0.042 
UL55 UL32-b 0.1 0 0.032 
UL86-a 0.1 0 0.013 
CD8 IE1 UL151 0.3 0 0.043 
UL28 0.5 0 0.018 
UL54 US29 0.7 0 0.043 
UL55 US32 1.4 0.2 0.014 
Frail+ CD4 gB UL48 pool 0 0 0.043 
UL55-a 0 0.5 0.044 
UL82 0.1 0 0.043 
IE1 UL55-a 0 0.2 0.024 
CD8 gB UL153 0 1.3 0.032 
US29 0 2.2 0.043 
US32 0.1 2.7 0.044 
UL54 UL123 0.2 1.3 0.046 
UL48 pool 0 0.3 0.044 
UL48-d 0 0.2 0.043 
UL48-e 0 0.1 0.043 
UL55-a 0 0.1 0.044 
HIV+ Frail− CD4 UL55 UL122 0 0.4 0.036 
UL48 pool 0 0.2 0.032 
UL48-d 0 0.3 0.035 
CD8 IE1 UL123 2.3 0 0.04 
UL54 US3 0 0.7 0.025 
UL55 UL32-a 0.1 0 0.036 
Frail+ CD4 gB UL48-b 0 0.1 0.05 
UL54 SEB 5.9 3.4 0.037 
CD8 UL54 UL55-a 0.1 0 0.047 
US32 0.3 0 0.036 
Data are the median percentages of CD4 or CD8 T cell responses to CMV stimulation 
Bold = the higher T cell response between donors with detectable or with undetectable 
CMV DNA. 
SEB= Staphylococcal Enterotoxin B 
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Table 3.18.  Significant Differences in the Frequency of T Cells Producing IL-2 in 
Response to CMV Peptides Between Donors with Detectable CMV DNA and Those 










detectable CMV  
Donors with 
detectable CMV  
P 
value 
HIV−  Frail− CD4 IE1 UL32-a 0.04 0 0.042 
UL54 UL48 pool 0 0.11 0.036 
CD8 gB SEB 1.98 4.89 0.043 
IE1 UL151 0.04 0 0.042 
UL54 UL48-b 0 0.06 0.048 
UL48-c 0 0.28 0.035 
UL55 UL28 0.15 0 0.032 
UL32-a 0.02 0 0.031 
UL82 0.01 0 0.031 
UL94 0.03 0 0.032 
UL99 0.02 0 0.031 
UL103 0.03 0 0.047 
UL153 0.03 0 0.01 
US29 0.12 0 0.017 
US32 0.22 0 0.014 
Frail+ CD4 gB UL32-a 0.07 0 0.046 
UL86-a 0.09 0 0.043 
UL122 0.03 0 0.043 
IE1 UL55-a 0.01 0.06 0.024 
UL122 0.04 0 0.035 
UL54 US3 0 0.44 0.022 
CD8 IE1 UL86-a 0.04 0 0.021 








CD4 gB SEB 6.37 18.9 0.037 
UL86-b 0 0.22 0.026 
US32 0 0.08 0.019 
UL54 UL82 0 0.04 0.045 
UL55 UL36 0.02 0.41 0.036 
UL48 pool 0 0.16 0.015 
UL48-a 0 0.1 0.025 
UL48-b 0 0.17 0.024 
UL48-c 0 0.08 0.032 
UL94 0 0.21 0.046 
UL99 0.02 0.13 0.036 
UL103 0.02 0.13 0.054 
UL122 0 0.17 0.045 
Total 0.64 4.24 0.04 
CD8 UL54 UL55-a 0 0.17 0.032 
UL82 0 0.33 0.025 
UL55 UL94 0 0.19 0.025 
Frail+ CD4 UL55 UL32-b 0.01 0.49 0.034 
CD8 UL54 UL83 0.04 0.42 0.036 
Data are the median percentages of CD4 or CD8 T cell responses to CMV stimulation 
Bold = the higher T cell response between donors with or without detectable CMV DNA. 
SEB= Staphylococcal Enterotoxin B 
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Table 3.19.  Significant Differences in the Frequency of T Cells Producing TNF in 
Response to CMV Peptides Between Donors with Detectable CMV and Those with 










detectable CMV  
Donors with 
detectable CMV  
P 
value 
HIV−  Frail− CD4 gB UL48-a 0.04 0 0.047 
UL48-e 0.02 0 0.047 
UL54 UL122 0.04 0 0.043 
UL55 UL86-a 0.04 0 0.018 
CD8 gB UL48-e 0.03 0 0.026 
UL86-a 0 0.01 0.047 
UL103 0 0.1 0.038 
IE1 UL32-a 0.03 0 0.043 
UL151 0.11 0 0.018 
UL54 UL32-b 0 0.03 0.034 
UL36 0 0.05 0.011 
UL48 pool 0.01 0.14 0.035 
UL48-a 0 0.09 0.015 
UL48-d 0 0.1 0.015 
UL55 UL28 0.38 0 0.032 
US29 0.49 0.01 0.049 
US32 0.71 0.03 0.014 
Frail+ CD4 gB SEB 9.93 18.17 0.046 
UL55-a 0.03 0.53 0.043 
IE1 UL32-b 0.04 0.01 0.046 
CD8 UL54 UL48 pool 0.02 0.27 0.044 
UL48-d 0.01 0.15 0.04 
UL55-a 0.01 0.11 0.043 
HIV+ Frail− CD4 UL55 UL28 0.03 0.31 0.035 
UL48-d 0 0.34 0.032 
UL48-e 0 0.09 0.036 
UL55-b 0.06 0.3 0.055 
UL123 0.01 0.21 0.037 
UL151 0.01 0.24 0.052 
CD8 UL54 US3 0.01 0.62 0.038 
UL55 SEB 23.6 10.76 0.04 
Frail+ CD4 gB SEB 7.04 23.83 0.037 
IE1 UL83 0.26 0 0.04 
UL54 SEB 8.32 1.93 0.037 
CD8 IE1 UL123 1.41 0.01 0.04 
UL54 SEB 13.71 8.13 0.037 
UL48-b 0 0.05 0.055 
UL55-b 0 0.12 0.047 
UL99 0 0.33 0.025 
UL55 UL103 0 0.14 0.031 
US24 0.03 0 0.033 
Data are the median percentages of CD4 or CD8 T cell responses to CMV stimulation 
Bold = the higher T cell response between donors with or without detectable CMV DNA. 
SEB= Staphylococcal Enterotoxin B 
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Table 3.20.  Significant Differences in T Cell Responses to Stimulation with CMV 
Peptide when the Related CMV DNA is Detected 
This table shows which CMV DNA was detected or not detected, which peptide stimulated 
the T cell response, whether the significant response was in the whole cohort or which HIV 
frailty subgroup, which T cell population had the response and what the response was. 
CMV DNA 
DNA detected 











gB − UL55 HIV− frailty+ CD4 IFNγ 
+ TNF 
UL55 + UL55 Whole cohort CD4 IFNγ 
IL-2 
HIV+ frailty− TNF 
IE1 − UL122 Whole cohort CD4 IFNγ 
IL-2 
TNF 
UL123 CD8 IFNγ 
IL-2 
TNF 
HIV+ frailty+ IFNγ 
 TNF 
UL122 HIV− frailty+ CD4 IL-2 
UL123 = IE1; UL122 = IE2 
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Table 3.21.  Differences in T Cell IFNγ Responses to CMV Peptide Stimulation Between HIV-Frailty Subgroups, for Donors 










































0.071 0.126 0.115 0.086 0.021 0.101 0.044 0.237 
SEB 0.173 0.223 0.269 0.057 0.021 0.753 0.048 0.423 
UL103 0.814 0.166 0.969 0.411 0.618 0.049 0.92 0.462 
UL32-b 0.025 0.365 0.016 0.766 0.093 0.181 0.044 0.782 
UL82 0.004 0.513 0.03 0.814 0.029 0.726 0.006 0.3 
UL86-a 0.037 0.801 0.28 0.202 0.059 0.5 0.024 0.703 
UL86-b 0.018 0.626 0.213 0.254 0.026 0.536 0.018 0.411 
CD8 UL122 0.092 0.198 0.134 0.257 0.043 0.818 0.213 0.323 
UL28 0.007 0.083 0.059 0.501 0.015 0.557 0.006 0.356 
UL32-a 0.591 0.183 0.772 0.157 0.33 0.046 0.481 0.556 
UL36 0.063 0.9 0.08 0.553 0.04 0.934 0.553 0.102 
UL48-b 0.927 0.054 0.872 0.049 0.654 0.176 0.829 0.436 
US3 0.173 0.709 0.039 0.128 0.494 0.266 0.319 0.324 
Differences in the CD4 or CD8 T cell IFNγ response to CMV peptides in donors either without detectable or with detectable CMV DNA 
between HIV-frailty subgroups.  Differences were measured by a Kruskal-Wallis test.  




Table 3.22.  Differences in T Cell IL-2 Responses to CMV Peptide Stimulation Between HIV-Frailty Subgroups, for Donors 




































CD4 SEB 0.062 0.232 0.022 0.228 0.033 0.423 0.02 0.195 
UL32-a 0.082 0.279 0.169 0.984 0.18 0.94 0.047 0.884 
UL55-a 0.241 0.39 0.431 0.799 0.517 0.847 0.039 0.459 
UL86-b 0.079 0.994 0.389 0.261 0.066 0.611 0.036 0.305 
CD8 UL86-a 0.305 0.049 0.717 0.115 0.791 0.321 0.504 0.172 
UL94 0.848 0.321 0.892 0.774 0.328 0.049 0.989 0.266 
Differences in the CD4 or CD8 T cell IL-2 response to CMV peptides in donors either without detectable or with detectable CMV DNA 
between HIV-frailty subgroups.  Differences were measured by a Kruskal-Wallis test.  
Bold = significant difference (p value <0.05) 
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Table 3.23.  Differences in T Cell TNF Responses to CMV Peptide Stimulation Between HIV-Frailty Subgroups, for Donors 





































CD4 UL86-a 0.046 0.718 0.26 0.2 0.367 0.118 0.397 0.338 
UL86-b 0.106 0.8 0.681 0.261 0.196 0.301 0.045 0.606 
US24 0.1 0.673 0.121 0.049 0.374 0.124 0.223 0.61 
US29 0.419 0.671 0.99 0.049 0.744 0.068 0.786 0.471 
CD8 UL28 0.055 0.384 0.046 0.929 0.086 0.048 0.093 0.718 
UL36 0.27 0.886 0.049 0.212 0.192 0.744 0.526 0.348 
UL86-b 0.023 0.064 0.003 0.49 0.035 0.054 0.021 0.199 
UL99 0.117 0.383 0.032 0.383 0.62 0.088 0.205 0.45 
US3 0.049 0.126 0.009 0.205 0.049 0.4 0.093 0.425 
Differences in the CD4 or CD8 T cell TNF response to CMV peptides in donors either with undetectable or with detectable CMV DNA 
between HIV-frailty subgroups.  Differences were measured by a Kruskal-Wallis test.  






 Importance of the Project A.
The introduction of HAART has helped people live longer with HIV infection, but has led 
to a rise in HANA conditions, such as frailty.  Chronic inflammation is a hallmark of HIV 
infection and frailty, with common serological inflammatory markers TNF, IL-6, and CRP 
elevated in both conditions.  Although the inflammation is reduced in HIV+ people 
receiving HAART compared to HIV+ people not receiving HAART, chronic inflammation 
persists and can cause severe cell and tissue damage.  A common etiology for the chronic 
inflammation present in both HIV infection and frailty could be a persistent viral infection, 
such as CMV.  The prevalence of CMV in nearly all HIV+ and frail people and the ability of 
the virus to elicit a strong cellular immune response, make CMV a good candidate for 
causing, at least in part, the chronic inflammation.  Understanding the causes of this chronic 
inflammation could lead to therapies that reduce or prevent chronic inflammation.  Such 
therapies would be a significant benefit, not just to the growing number of people living 
longer with HIV, but also to the HIV− elderly population and people with other conditions 
(such as atherosclerosis and cancer) where inflammation is a significant problem. 
 
This project built on previous studies, including the work of Margolick et al. (8) (discussed in 
more detail in the Introduction), which reported that the increased number of CMV-
responsive T cells could influence the chronic inflammation seen in both HIV-infected and 
HIV− men.  Although the CD4 and CD8 T cells from all of the donors tested in the study 
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by Margolick et al. (8) responded to at least some of the CMV peptides tested, the presence 
of CMV in these donors was not tested.  This left unanswered the important question of 
whether the amount of CMV present accounts for the differences in the frequency of CMV-
responsive T cells.  By quantifying the CMV DNA and comparing it with known T cell 
response data, this project aimed to improve our understanding of the role CMV plays in the 
pathogenesis of inflammation. 
 
 Validating the ddPCR Assay B.
1. Assessing the Sensitivity of the ddPCR Assay  
After an initial lytic phase of infection, CMV enters a latent phase with minimal replication 
of its viral genes.  It has yet to be fully established which cells the latent CMV resides in.  
The lack of replicating virus and the very small number of infected cells meant a highly 
sensitive assay would be needed.  In ddPCR, the DNA in a specimen is separated into 
20,000 nanoliter-sized droplets, so that each droplet gets approximately one copy of the 
template DNA.  By separating the template DNA into so many droplets, non-specific 
background DNA is reduced, which improves the PCR conditions.  This helps make the 
ddPCR assay more sensitive than other PCR assays (e.g., RT-PCR) at detecting rare DNAs.  
The ability of ddPCR to provide an absolute quantitation of the DNA concentration without 
the need for an external standard, as discussed in the Methods, also makes the ddPCR assay 
a valuable method to quantify rare DNAs. 
 
When the project was started, ddPCR was a new technique that needed validation to 
determine how sensitive and accurate it was before it could be reliably used on the samples.  
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A recently published paper that used ddPCR to measure CMV (119) was used as the starting 
point for developing the assay. 
 
The availability of the IE1 primers that previously had been used by Dr. Leng to detect 
CMV using nested PCR (124) and the importance of IE1 in viral replication made IE1 a 
good target to start with to establish how effective the ddPCR was at detecting CMV DNA.  
Using a series of 10-fold serial dilutions of genomic AD169 CMV that was newly purchased, 
ddPCR could detect 1 copy of CMV DNA (Figure 3.1).  Using HFFs infected with CMV at 
multiple MOIs, CMV DNA could be detected by ddPCR at low copy number (Figure 3.2).  
The sensitivity of the ddPCR assay to detect CMV at low levels led to the testing of PBMC 
DNA for CMV DNA.  However, it was more difficult to detect CMV DNA in PBMC when 
it was unknown if CMV DNA was present, and even if present was likely to be at very low 
levels.  The challenge was to distinguish low levels of CMV DNA from nonspecific binding 
of the primers or the probe, that lead to fluorescence which was not due to binding to CMV 




2. Determining the Specificity of the Primers and Probes Used in the 
ddPCR Assay 
The presence of positive fluorescent droplets in known CMV− samples, after the 
background had been accounted for, raised questions over the accuracy of the positive signal 
(Figure 3.6).  CMV DNA in PBMC is so rare that it may be represented by only one or two 
droplets.  The verity of a positive droplet in a sample could be undermined by any false-
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positive droplets detected in the negative controls.  The importance of having negative 
controls that were reliably clear of any positive droplets meant much time was spent on 
ensuring the cleanest possible laboratory environment to avoid any possibility of 
contamination of the samples.   
 
Testing CMV− samples helped determine the specificity of the primers and probes used.  
These samples were either from donors who had been confirmed to be CMV− by an ELISA 
or nested PCR, such as PBMC from a CMV− leukopak, or mouse tail DNA which cannot 
be infected with human CMV.  While the background levels varied between the primers and 
in each CMV− sample, the gB probe consistently had negligible background levels (Figure 
3.7).  Using known CMV− samples as negative controls in subsequent experiments in 
addition to the NTC, served as a better negative control than the NTC alone.  The 
background levels of the primers had to be accounted for and subtracted from any positive 
signal measured by the primers.  However, using multiple negative controls provided the 
best gauge of the background levels and increased the likelihood that the positive droplets 
truly were due to the detection of CMV DNA. 
 
3. Determining the Optimal Amount of Genomic DNA in Each Well 
To maximize the chance of detecting CMV DNA, the amount of DNA that could be loaded 
in each well was determined.  This amount was determined to be 50 ng, based on the finding 
that at this amount CMV DNA could be detected while preserving good separation between 
positive and negative droplets (Figure 3.4).  This separation is important as the negative 
droplets must be low enough to clearly identify positive fluorescent droplets.  Higher 
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amounts of DNA were tested, but the separation between the positive and negative droplets 
was poorer compared to the 50 ng.   
 
4. Determining which Primers to Use in the ddPCR Assay 
As previously mentioned, IE1 was a good primer to start with as it had been used previously 
by Dr. Leng to detect CMV DNA by nested PCR (118).  In addition to IE1, other primers 
were selected for study through literature searches or by their significance in CMV 
replication.  UL54 and UL55 primers were selected for study based on a paper that 
compared multiple primers to different CMV genes, and these primers were determined to 
be the most sensitive and specific (123).  US28 primers were tested as UL28 is an important 
CMV gene expressed both during the viral lytic replication and during latency.  In initial 
experiments, the US28 primer detected high levels of CMV DNA.  However, testing the 
CMV+ and CMV− samples showed that detection of US28 DNA was not specific to 
CMV+ cells, because there was no difference in detection between the CMV− and the 
CMV+ donors (Figure 3.6).  
 
 It would be worth designing new primers or probes that are more specific to determine the 
amount of US28 DNA present.  The ability of the virus to remain latent the majority of the 
time in an infected person, makes it important to study those few genes that are expressed 
by the virus during latency, such as US28.  This may provide insight into the role that these 




5. Incorporating the gB Probe into the ddPCR Assay 
The gB probe was incorporated into the assay as it had been used by another collaborator to 
detect CMV DNA (119).  It used a different method of fluorescently tagging the target 
DNA that was hypothesized to be more specific and reduce the background levels.  As 
previously discussed in the Methods, the probe binds to a target sequence already amplified 
by gene specific primers and during the extension phase the reporter attached to the probe is 
cleaved, allowing the reporter to fluoresce.  The gB probe tagged with FAM allowed the use 
of a HEX-tagged RPP30 probe in the same well.  Having the RPP30 in the same well as the 
CMV improved the accuracy of determining the sample cell number.  It also allowed more 
samples to be tested on a plate.   
 
As previously discussed, the gB probe had negligible background levels in the CMV− 
samples, indicating that the specificity of the probe was higher than that of the primers 
(Figure 3.7d).  When tested in the same sample, the amount of gB DNA detected closely 
matched the amount of UL55 DNA detected (Figure 3.8), validating the results obtained by 
both the probe and the primers.  Although the background levels always needed to be 
subtracted from the CMV levels detected by the primers, which was not a problem with the 
gB probe, the comparable levels of CMV DNA detected by the gB probe and the primers, 
especially at high copy numbers of CMV DNA, provides confidence in the results obtained 




6. Confidence in the Results of the ddPCR Assay  
The accuracy of the ddPCR results was further supported by the use of nested PCR to 
confirm the ddPCR results (Figure 3.3).  Nested PCR was performed using the same IE1 
primers used in the ddPCR assay for the second round of nested PCR reactions.  CMV+ 
samples positive by ddPCR were also positive for IE1 by nested PCR, while the CMV− 
sample was negative by both methods.  
 
Multiple CMV primers and the gB probe showed little intra-sample variation, which helped 
corroborate each other’s results.  In PBMC and semen, nearly all samples were positive for 
more than one CMV primer or probe.  All samples that were positive for the gB probe were 
positive for at least one CMV primer.  The amount of CMV DNA detected was also very 
similar between the primers and the gB probe, especially at higher concentrations of CMV 
DNA.  In the semen samples the median amount of CMV DNA detected by IE1, UL54, 
UL55, and gB probe was 1.13, 1.09, 1.38 and 1.15x104 copies/106 cells respectively.  The 
variation seen in the amount of CMV genes detected could be due to differences in 
sensitivity of each primer.  However, the amount of CMV DNA detected by the UL55 
primer strongly correlated with the amount of CMV DNA detected by the gB probe (Figure 
8).  As the UL55 and the gB probe are targeting the same gene, these results corroborate 
each other.  This provides confidence in the results of the assay to detect CMV DNA.  
 
 The variation in the amount of CMV detected may also be due to the absence of the viral 
genes from the cell.  It is possible that the donors are infected with different strains of the 
virus, or that during infection of the cell or during latency portions of the viral genome may 
be lost.  For example, the commonly used laboratory CMV strain AD169 has a section of its 
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genome missing.  The missing section encodes 19 ORFs that are present in clinical isolates, 
which prevent AD169 from replicating in cell types that are permissive for replication by 
clinical strains (125).  While many ORFs are highly conserved between CMV strains, there is 
also substantial variability in the ORF sequences between CMV strains (126).  Different viral 
strains may be detected better by some primers than others, depending on the variation in 
the target gene and how sensitive and specific the primer is.  The consistently low 
background of the gB probe allowed the detection of droplet clusters of different 
fluorescent intensities in some samples, which may indicate variants of CMV.  
 
 To investigate the prevalence of different clinical CMV strains, a study of 53 
immunocompetent women who had recently seroconverted to CMV identified a single 
clinical strain in 51/53 women based on UL55 sequencing (127).  Over the 3 years that these 
women were followed, the same strain was present in each isolate tested.  None showed 
signs of acquisition of new strains or sequence changes.  Five subtypes of gB alone were 
identified in this study, and when this was combined with sequencing of 2 additional loci 
(UL144 and UL146), 32/53 women had their own unique strain of CMV (127).  While the 
presence of multiple strains is uncommon in immunocompetent individuals, multiple strains 
have been identified in people with AIDS (128) and transplant recipients (129).  Geographic 
and demographic variation can affect the gB genotype distribution (130); however, different 
genotypes have not been shown to have an effect on the clinical disease (131).  Sequencing 
the CMV DNA from donors would reveal differences in the CMV strains that may help 
explain the variety of T cell responses seen to CMV DNA.  
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 The Relationship Between CMV DNA and HIV and C.
Frailty 
This work aimed to take advantage of a small but well-characterized cohort of donors in the 
SHARE study (8).  The frequency of CMV-responsive T cells was measured in PBMC.  All 
donors had both CD4 and CD8 T cells responding to CMV peptide stimulation, regardless 
of HIV serostatus or frailty status.  Levels of responsive T cells correlated with certain HIV 
and frailty subgroups.  Higher levels of CD4+ T cells producing IL-2 in response to CMV 
stimulation predicted the onset of frailty in HIV− frailty− donors but not in HIV+ frailty− 
donors (8).  This project aimed to build on that study by understanding how the presence of 
CMV DNA is related to the T cell responses to CMV. 
 
As detailed in the Results, the present study showed that there were no significant 
differences in the amount of CMV DNA detected in PBMC between HIV+ and HIV− 
donors (8) (Figure 3.10a) or between frail and non-frail donors (Figure 3.10b).  There were 
also no significant differences in the amount of CMV DNA detected in PBMC by any of the 
primers or the probe between the 4 subgroups: HIV− frailty−, HIV+ frailty−, HIV− 
frailty+, HIV+ frailty+ (Figure 3.11a-d).  The lack of significant differences in the amount of 
CMV DNA detected in PBMC between HIV+ and HIV−, frailty+ and frailty−, and in the 
HIV-frailty subgroups suggests that detection of CMV DNA is not related to HIV or frailty 
status.  Although the differences between some of the groups were not significant using a p-
value cutoff of 0.05, some subgroups did show differences that were close to being 
significant, such as the amount of UL55 DNA in frailty− compared to frailty+ (Table 3.4), 
or IE1 DNA between HIV+ frailty− donors and both the HIV− frailty− donors and the 
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HIV+ frailty+ donors (Table 3.6), and gB DNA between the HIV− frailty− and the HIV+ 
frailty+ donors (Table 3.12).  
 
 It is possible that the small sample size and the variation within the groups for each gene 
could explain why the differences seen were not significant.  The magnitude of the 
differences varied greatly within the groups analyzed.  In many groups studied, there were 
either a majority or at least a large number of donors who had no CMV DNA detected.  
This varied between the specific primers and the probe tested.  The variability in the amount 
of CMV DNA in PBMC detected between donors of the same group may have resulted in 
significant differences between the groups being missed.  If a type II error has occurred, this 
could be addressed by studying a larger sample size.  Studying a larger sample size may help 
resolve whether significant differences present in the current cohort hold up when more 
people are included in the study.  It may also clarify whether differences that were close to 
the 0.05 p-value cutoff were actually significant or not.  
 
 The Detection of CMV DNA Correlates with Specific D.
CMV-Stimulated T Cell Responses 
1. T Cell Responses to CMV Stimulation when DNA is Detected 
 The relationship between the detection of CMV DNA in donors and their T cell responses 
to CMV stimulation, was found in all HIV-frailty subgroups and was independent of HIV or 
frailty status.  Although the detection of CMV DNA was not affected by frailty status when 
viewed at the whole cohort level, stratification of the cohort revealed significant differences 
not previously seen.  This may indicate that while the detection of CMV DNA alone may 
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not be related to frailty, it may have an effect on specific cell populations in people with or 
without HIV infection.  The detection of certain CMV DNAs, such as UL55, was associated 
with certain T cell responses that could be identified in the whole cohort and in specific 
subgroups, such as the HIV+ frailty− subgroup.  The number of CD4 IL-2 producing cells 
was higher when UL55 DNA was detected, in the whole cohort and in HIV+ frailty− 
donors (Table 4.1).  When UL55 DNA was detected, the number of CD4 cells producing 
IFNγ and TNF was also significantly higher.  The detection of other CMV DNAs in PBMC 
from donors also showed significant differences in the number of CD4 and CD8 CMV-
responsive cells.  Donors in whom UL54 was detected had significantly higher number of 
CD8 T cells producing TNF in responses to CMV, than donors in whom it was not 
detected.  This association was present when the whole cohort was studied and in multiple 
HIV-frailty subgroups (Table 4.1).  These results showed that the detection of different 
CMV DNAs was linked to varied T cell responses to CMV stimulation.   
 
The ability of different CMV genes to have varied effects on the T cell responses to CMV 
stimulation has not been reported.  These different responses may be due to the generation 
of abortive CMV transcripts that stimulate a T cell response, or the activation of innate 
immune sensors that trigger multiple different signaling pathways resulting in different 




Table 4.8.  Examples of Significant Differences T Cell Responses when CMV DNA 
is Detected  
This table shows which CMV DNA was detected, whether the significant response was in 
the whole cohort or specific HIV-frailty subgroup, which T cell population had the 
response, and what the response was. 
CMV DNA detected  Group or subgroup T cell Cytokine response 
gB HIV− frailty+ CD8 IFNγ 
CD4 TNF 
HIV+ frailty- IL-2 
UL55 HIV+ frailty- CD4 IFNγ 
Whole cohort Total CD4 IL-2 
CD4 
HIV+ frailty- Total CD4 IL-2 
CD4 
TNF 
UL54 Whole cohort CD4 TNF 
CD8 





2. T Cell Responses when the Stimulating CMV Peptide is Related to the 
DNA Detected 
T cell responses showed significant differences between donors with detectable CMV DNA 
and those donors without CMV DNA, when the CMV DNA detected and the peptide used 
to stimulate the T cell response were from the same gene (Table 3.20).  Donors with 
detectable UL55 DNA had significantly higher numbers of CD4 cells producing IFNγ and 
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IL-2 in response to UL55 than donors with undetectable UL55 DNA (Table 3.15).  HIV+ 
frailty− donors with detectable UL55 DNA had significantly higher numbers of CD4 cells 
producing TNF in response to UL55 than donors with undetectable UL55 DNA (Table 
3.19).  These data are supported by the data which showed that HIV− frailty+ donors with 
detectable gB DNA, had significantly higher numbers of CD4 cells producing TNF in 
response to UL55 than donors with undetectable gB DNA (Table 3.19).  A significant 
difference between the HIV-frailty subgroups was seen in donors with undetectable gB 
DNA, who had a higher number of CD4 cells producing IL-2 in response to UL55 peptide 
stimulation (Table 3.22).  UL55 primers and gB probe both target the UL55 gene, which 
encodes the gB protein (as previously discussed), suggesting a link between the detection of 
UL55 DNA and T cell responses to UL55.  
 
3. T Cell Responses to CMV when CMV DNA is Not Detectable 
While the detection of UL55 DNA was linked with the T cell responses to UL55, donors 
with undetectable IE1 DNA had significantly higher number of responsive-T cells to either 
IE1 (CMV gene UL123) or related IE2 (CMV gene UL122).  Donors with undetectable IE1 
DNA had significantly higher numbers of CD4 cells producing IFNγ, TNF, and IL-2 in 
response to UL122 than donors with detectable IE1 DNA (Table 3.13).  Donors with 
undetectable IE1 DNA had significantly higher numbers of CD8 cells producing IFNγ and 
IL-2 in response to UL123 than donors with undetectable IE1 DNA (Table 3.13).  IE1 and 
IE2 are related proteins with similar functions.  However, it appears that UL122 (IE2) was 
associated with a response in CD4 cells while UL123 (IE1) was associated with a CD8 
response.  It is unclear how this may be occurring, though presentation of IE1 peptides on 
MHC-I or IE2 peptides on MHC-II would activate CD8 or CD4 T cells, respectively. 
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T cell responses to CMV when CMV DNA is not detected in PBMC may indicate that CMV 
DNA is present in other parts of the body, where it can stimulate T cells.  This could explain 
how the T cells are being activated even though the DNA is not detected in the PBMC.  To 
test this, cells from different locations in the body could be isolated, such as the lungs and 
the spleen where CMV has previously been found (132), and compared between individuals 
that have detectable CMV DNA and those with undetectable CMV DNA. 
 
 Possible Mechanisms by which CMV DNA Could E.
Affect T Cell Responses 
CMV DNA may influence CD4 and CD8 T cell responses by a variety of mechanisms.  One 
way that CD4 and CD8 cells are activated is by specific antigens.  This requires the 
expression of viral peptides that are then presented on either MHC-II or MHC-I to CD4 or 
CD8 cells, respectively.  The transcription of the CMV DNA and translation into viral 
proteins could stimulate CD4 and CD8 cells.  However, CMV infection in these donors is in 
a latent phase, resulting in the expression of very few viral proteins.  It is possible that the 
virus starts replicating but undergoes abortive transcription and only small messenger RNAs 
(mRNAs) are made (133).  These could be translated into the viral peptides that stimulate 
the host immune response.  This could explain why T cells have significant responses to the 
UL55 peptide pool in the presence of UL55 DNA and why some people have up to 30% 
CMV-specific T cells.  To test whether abortive transcription is occurring in cells latently 
infected with CMV, very low levels of CMV RNA would need to be measured, which would 
require a very sensitive assay.  It is possible that ddPCR may be sensitive enough to detect 
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these abortive transcripts.  Reverse transcriptase would be needed to convert RNA into 
cDNA that could be detected by ddPCR. 
 
In addition to abortive transcripts generating CMV peptides that stimulate the immune 
response, CMV DNA could trigger innate immune sensors that lead to different immune 
responses.  Pattern recognition receptors (PRRs) such as interferon gamma-inducible factor 
16 (IFI16), which is localized to the nucleus, can bind dsDNA (134).  IFI16 has been shown 
to bind to the promoter of the UL54 gene, downregulating viral replication (135).  IFI16 
binding to dsDNA leads to the activation of the ASC-Caspase 1 inflammasome in the 
cytosol (136) and the induction of IFNβ in macrophages (137).  IFI16 and cyclic GMP-AMP 
synthetase (cGAS) cooperate in macrophages to produce the second messenger cyclic GMP-
AMP (cGAMP).  cGAMP docks onto the endoplasmic reticulum-bound protein stimulator 
of interferon genes (STING) (138).  IFI16 ensures that sufficient cGAMP is present for 
STING activation.  IFI16 also recruits TANK-binding kinase 1 (TBK1) to the STING 
complex, ensuring STING downstream signaling (138).  STING signaling involves the 
activation of multiple pathways including the phosphorylation of IRF3 and IFN production 
(139).  Recent studies have reported that CMV induced cGAS in monocytes (140) and that 
cGAS-STING signaling is important in the initial innate response to control CMV infection 
(141). 
 
The recognition of different CMV genes by PRRs such as IFI16 in the nucleus, possibly 
through their different GC content, could trigger innate immune responses or signaling 
pathways that result in different T cell responses to CMV.  Differences in signaling pathways 
could result in the same cytokine being produced in response to different CMV DNAs, such 
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as TNF produced by CD4 T cells when either gB or UL54 DNA was detected.  This could 
also explain how different cytokines can be produced in response to the same CMV DNA; 
e.g., IL-2, IFNγ, or TNF were all produced by CD4 cells in response to UL55 when UL55 
DNA was detected.  To test this, donors who have UL54 CMV DNA could be compared to 
donors with undetectable UL54.  IFI16, which has been reported to bind to the UL54 
promoter, could be expressed at higher levels in donors with UL54 detected.  A proteomic 
array comparing donors who have CMV DNA to those without detectable CMV DNA may 
also detect key proteins involved in the signaling pathways that result in different immune 
responses to CMV.   
 
 Limitations of the Project F.
Among the limitations of this project, the small sample size limited the ability to detect 
significant effects that may become apparent if more samples were tested.  It is also possible 
that significant relationships described in this work may not be maintained if studied in a 
larger cohort. 
 
This project only studied CMV DNA and a handful of the potential genes in the large viral 
genome.  This means that other genes that may be playing a role in influencing the T cell 
responses could have been missed.  
 
A report by Parry et al. (112) suggested that the detection of CMV DNA in PBMC increased 
dramatically in people aged 70 and older.  The average age of the group in the present study 
was only 61.7 and only 3 donors were aged 70 or older.  Therefore, this project could not 
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address the impact that being over 70 years old has on CMV DNA detection in the blood.  
Investigating elderly individuals may help to detect more CMV DNA and better understand 
its role in inflammation and aging.  With new therapies extending the average life expectancy 
for HIV-infected individuals so that it is similar to the uninfected population (18), more 
samples from older donors will be available for testing. 
 
Another limitation of the present study was that not all physiological tissues where CMV 
may be found or persist in some form of latent infection were tested.  As previously 
discussed, tissues such as the lungs and the gut have been identified recently as places that 
CMV may reside (132).  Testing these areas in which CMV is highly likely to be found may 
help determine the role CMV plays in the immune response. 
 
This work is just a step forward in understanding the interactions between CMV DNA and 
the immune response.  The ability of a viral peptide to stimulate multiple responses that vary 
depending on which CMV genes are detected, suggests an important role for the CMV 
DNA in the inflammatory response seen in HIV infection and frailty.  Further research is 
needed to fully understand these interactions. 
 
 Future Plans G.
This project suggests that CMV DNA may be playing an important role in the specific T cell 
responses to CMV infection.  One possibility is that DNA is directly stimulating T cells; 
however, the ability of CMV DNA to trigger T cell responses has not previously been 
shown.  This project raises this possibility but further research is needed. 
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A next logical step would be to improve our current understanding of how DNA could be 
triggering these T cell responses, by measuring CMV RNA levels in people with CMV DNA.  
The detection of CMV RNA would indicate that transcription of the viral DNA was 
occurring.  The production of ‘abortive transcripts’ that are subsequently translated into 
peptides that stimulate T cells, would require a sensitive assay to be detected.  Determining 
which RNAs were being transcribed and whether they are related to the CMV DNA that is 
detected would help explain how the CMV DNA is influencing T cell responses.  The 
production of more viral RNA in latently infected cells would also expand our understanding 
of latency and how it is maintained by the virus.  This may have implications for other 
herpes viruses that can persist latently, such as Epstein-Barr Virus (EBV). 
 
Another mechanism that CMV DNA may use to trigger T cell responses could be through 
DNA sensors that can recognize viral DNA and initiate signaling pathways, resulting in 
altered T cell responses.  These DNA sensors that localize to the nucleus could be 
discovered through proteomic arrays that compare donors with and without detectable CMV 
DNA.  The identification of any proteins would require confirmation that they play a 
potential role in mediating the T cell response when CMV DNA is detected.  Small 
interfering RNA (siRNA) could be used to knock down the target gene in a cell where the 
CMV DNA is detected and then see how the T cells respond to CMV stimulation.  
 
To further understand the possible relationship between CMV DNA, including UL55, and 
the inflammatory response, inflammatory markers could be compared between donors with 
and without detectable CMV DNA.  A panel of serologic inflammatory cytokines and 
chemokines, such as the one previously used (7), could provide even more detail into the 
 126 
impact specific CMV DNA have on the immune response.  Donors with detectable CMV 
DNA may have higher T cell responses and elevated serological markers for inflammation, if 
CMV DNA plays a role in the inflammation.  Further work could also be conducted looking 
at the role UL55 plays in stimulating IL-2 production in CD4+ T cell and whether it is being 
expressed during latency, even at a very low level.  UL55 encodes gB, a highly conserved 
protein that is a major target for neutralizing antibodies (50).  This makes gB an important 








This project sought to tackle the important question of the effect that CMV DNA in PBMC 
has on the T cell responses to CMV infection, and the role of CMV in the chronic 
inflammation seen in treated HIV infection and aging.  To do so, it was necessary, first, to 
establish whether CMV DNA was detectable in PBMC.  Next, once this was verified, it was 
important to measure whether the amount of CMV DNA in the blood correlated with the T 
cell responses to CMV.  Another secondary aim was to see if these correlations were affected 
by HIV or frailty status. 
 
The number of CMV-specific T cells in a person can be between 10% and 20% of the CD4 
and CD8 T cells, or more in some people (48).  This percentage is very high compared to 
other viruses, such as HIV where the number of HIV-specific T cells is 1-4% (142, 143).  
Nevertheless, most immunocompetent people infected with CMV are asymptomatic.  In 
HIV-infected people, however, CMV infection can cause chronic inflammation that persists 
even after they receive HAART.  The number of CMV-responsive T cells, depending on the 
HIV-status and frailty-status of the donor, has been shown to correlate with inflammatory 
markers such as IFNγ, TNF, and IL-6 (8).  These interactions occur in most people while 
CMV is not actively replicating.  During this latent phase, no infectious virus is produced 
and CMV gene expression is significantly reduced with the expression of only a few genes 
confirmed to date (144).   
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Understanding how CMV which is not actively replicating can stimulate the immune 
response to such a high degree is a significant issue worthy of investigation.  Further 
research in this area may lead to therapies that could reduce the chronic inflammation caused 
by CMV.  For example, a CMV vaccine could help people through the normal aging process 
and HIV-infected people receiving treatment who still have higher inflammation than 
HIV−.  
 
The hypothesis for this project was that CMV DNA levels in PBMC are correlated with the 
number of CMV-responsive T cells.  Using the highly sensitive and quantitative ddPCR 
assay, CMV DNA was quantified in PBMC, and significant differences were seen in the T 
cell responses to CMV between those donors with and those without detectable CMV 
DNA.  Donors who had detectable UL54 DNA had significantly higher numbers of CD8 T 
cells producing TNF, compared to those donors with undetectable UL54 DNA, supporting 
the hypothesis.  However, significantly higher numbers of CMV-responsive T cells were also 
seen in some donors who did not have detectable CMV DNA.  For example, donors with 
undetectable IE1 DNA had significantly higher numbers of CD4 and CD8 T cells that 
produced IL-2 in response to CMV, compared to donors with detectable IE1 DNA. 
 
These data suggest that either the DNA could be associated with the T cell response, or the 
T cell response affects the presence of the CMV DNA.  Under the first theory, the CMV 
may undergo abortive transcription that could produce mRNA and subsequently produce 
proteins or peptides that could stimulate CMV-specific T cell responses.  Alternatively, CMV 
DNA may also be sensed by innate sensors such as IFI16, which can enter the nucleus and 
activate the inflammasome and downstream signaling pathways, resulting in stimulating T 
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cell responses.  The alternative could be that T cells are responsible for the amount of CMV 
DNA detected.  T cells with greater responses in donors with detectable CMV DNA than in 
donors without detectable CMV DNA, may be less effective at controlling CMV replication.  
On the other hand, T cells with greater responses in donors with undetectable CMV DNA 
than in those with detectable CMV DNA, may be controlling the virus better.  The cross-
sectional nature of this project cannot distinguish whether the CMV DNA is associated with 
the T cell responses or the T cells are controlling the levels of CMV DNA.  A longitudinal 
study that quantifies both the T cell responses to CMV and the amount of CMV DNA 
would be needed to answer this question. 
 
The use of ddPCR in this project enabled the detection of CMV DNA in PBMC, as had 
been shown previously.  Notably, 4 CMV genes were analyzed in this study, confirming and 
extending previous studies that had analyzed only one CMV gene.  In addition to detection 
of CMV DNA, this project was the first to quantify the CMV DNA as well.  The UL55 
primer and the gB probe were used to independently measure the same CMV gene, and 
comparable levels of CMV DNA in the same donor were found, validating the levels of 
CMV DNA measured.  However, the assay could have been strengthened by using either 
better primers or better positive controls.  Ideally, better primers, which would have less 
non-specific fluorescence, could be identified by testing primers that cover the entire gene or 
genome.  The most sensitive primers at detecting CMV DNA with the lowest background 
fluorescence could be used for future experiments.  
 
Identifying the best positive control sample, the “gold standard,” would more accurately 
define which fluorescent droplets accurately represented CMV DNA.  In this project, high 
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levels of CMV DNA were detected in the PBMC of HIV-infected men who had not 
received HAART.  As these HIV+ donors were not receiving HAART, they had high HIV 
viremia and suppressed immune systems, making it possible that the CMV was no longer 
latent in these donors and was actively replicating.  A better positive control would be a 
latent CMV sample with detectable CMV DNA, which would require the identification of 
CMV reservoirs.  One of the reservoirs where CMV can persist is CD34+ myeloid 
progenitor cells in the bone marrow; however, those cells are not easily accessible.  The 
lungs have been identified as another potential reservoir for CMV (132), and if the virus is 
latent in the lungs, CMV DNA from bronchial lavage samples could provide the gold 
standard for detecting latent CMV DNA. 
 
This project ultimately showed a link between the detectability of CMV DNA in PBMC and 
specific T cell responses.  A better understanding of this relationship could provide a 
foundation for therapies to alleviate chronic inflammation for many people, including HIV+ 
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